

**HEALTH PROFESSIONAL INFORMATION**

1. Vitamin K2-7 Monograph: Summary Product Information
2. Indication and Clinical Use
3. Dosage and Administration
4. Mode of action
5. Contraindications
6. Adverse effects
7. Overdosage
8. Stability and Storage
9. Packaging

**SCIENTIFIC INFORMATION**

1. Clinical trials
2. Detailed Pharmacokinetics
3. Toxicology
4. Important Studies and Guidelines
5. Reference


**HEALTH PROFESSIONAL INFORMATION**

**1. Uni- K2-7 Monograph: Summary Product Information**

Uni-K2-7 consists of Vitamin K2 homologue. The name "vitamin K" refers to a group of chemically similar fat-soluble compounds called naphthoquinones. Vitamin K occurs in two biologically active forms: phylloquinone (vitamin K1) and menaquinones (vitamin K2). Vitamin K1 is produced by green and leafy vegetables, and algae, whereas vitamin K2 is predominantly of microbial origin [1-2].

In addition to its role in the synthesis of hepatic blood coagulation proteins, vitamin K has been found to play a role in bone health, cardiovascular health, prevention of cancer, suppression of inflammation, prevention of brain oxidative damage, sphingolipid synthesis, and osteoporosis [3-7].

All K vitamins are similar in structure; they share a “quinone” ring, but differ in the length and degree of saturation of the carbon tail and the number of “side chains”. The number of side chains is indicated in the name of the particular menaquinone ; thus K2-7 refers to seven molecular units - called isoprene units - attached to the carbon tail and this influences the transport to different target tissues (**Figure 1**).



**Figure 1: Chemical Structure of Uni-K2-7**

**2. Indication and Clinical Use**

The use of Uni- K2-7 has been indicated in Coronary Arterial Disease with high risk of CHD for arterial calcification.

### **3. Dosage and Administration**

Uni K-2-7 is available in two doses; 50mcg and 100 mcg.

### **4. Mode of action**

**Matrix-Gla- Protein (MGP), Vitamin K and Cardiovascular Disease (CVD):**

- Among the proteins involved in vascular calcium metabolism, the vitamin K-dependent MGP plays a dominant role.
- MGP is synthesized primarily by chondrocytes and vascular smooth muscle cells and is found in the cartilage, bone and vasculature.
- MGPs, when carboxylated, play a key role in the inhibition of tissue calcification, thus becoming a very critical factor in plaque formation and reversal.
- Its pivotal importance for vascular health is demonstrated by the fact that there seems to be no effective alternative mechanism for calcification inhibition in the vasculature.
- Inadequate dietary intake of vitamin K may result in undercarboxylation of vascular MGP, leading to enhanced calcification of atherosclerotic lesions and, consequently, an increased risk of coronary heart disease [8].



**Figure 2: Role of Vitamin K and MGP in calcification**

**5. Contraindications**

- Generally, it is recommended that individuals on these medications limit Uni K-2-7 consumption to amounts typically found in the average diet (90-120 mcg).
- Pregnant women on warfarin, anticonvulsants, rifampin, or isoniazid place the newborn at increased risk of Uni K-2-7 deficiency as these medications can interfere with fetal Uni K-2-7 synthesis.
- Extended use of broad spectrum antibiotics may decrease Uni-K2-7synthesis by intestinal bacteria.
- Use of cephalosporins and salicylates may adversely affect Uni-K2-7recycling by inhibiting vitamin K epoxide reductase.
- Furthermore, absorption of Uni-K2-7may be decreased with the use of drugs such as cholestyramine, colestipol, orlistat, and substances such as mineral oil and the fat substitute, olestra.

**6. Adverse effects**

- From a large number of clinical trials using dosages in excess of 40 mg/day, there were no reports of side effects associated with any type of hypercoagulable state.
- Both animal and clinical studies support the conclusion that Uni-K2-7 has no abnormal hemostatic activity [9].

**7. Overdosage**

- A high intake of menaquinones does not increase thrombosis risk.
- Vitamin K-dependent proteins have a limited number of Glu residues capable of g-carboxylation per molecule, beyond which there can be no further g-carboxylation or excessive coagulation

**8. Stability and Storage**

- Protect from light and moisture. Keep away from children.

**9. Packaging**


- Each pack consists of three strips with 10 tablets each.

## SCIENTIFIC INFORMATION

### 1. Clinical trials

#### *Study 1: Rotterdam Study: Vitamin K2-7 in CVD* [10]

##### **Study Design:**




##### **End Point:**

- Dietary intake of Vitamin K2-7 and its effect on arterial calcification and cardiovascular mortality

**Result:**

- Arterial calcification was mild or absent in 64.3% of the patient pool; moderate in 30.4 % and severe in 5.4%.
- It was observed that with increase in the dietary intake of Vitamin K2-7, there was a decline in the arterial calcification as well as the cardiovascular mortality (**Figure 3**)



**Figure 3: Dietary Intake of Vit K2-7 and risk for event**

**Study 2:** Define optimal intake levels of menaquinone intake for various indices of cardiovascular health [11].

**Study Design:**

- Investigators randomly administered 360, 720 or 1080 µg of MK-7 thrice weekly for 8 weeks ( $\approx$  120, 240 and 360 µg/day) to 200 chronic haemodialysis patients.

**Endpoint:**

- To ascertain an appropriate dosage for MGP activation and subsequently the calcification inhibitory activity of MGP.

***Result:***

- At baseline, desphospho-uncarboxylated matrix Gla-protein (dp-uc-MGP) was not associated with phylloquinone intake ( $P = 0.92$ ), but correlated inversely with menaquinone intake ( $P=0.023$ ).
- Results also demonstrated that MK-7 supplementation dose dependently reduced dp-uc-MGP levels by 17, 33, and 46%, respectively, in haemodialysis patients.

***Study 3:*** To examine the efficacy of Vitamin K2-7 in healthy individuals [12]

***Study Design:***

- To examine potential efficacy in a normal population, investigated long-term effects of supplementation with 180  $\mu\text{g}/\text{day}$  MK-7 (MenaQ7,  $n=120$ ) or placebo ( $n=124$ ) on arterial stiffness in healthy postmenopausal women for three years in a double-blind, placebo-controlled trial.

***Endpoint:***

- Indices of local carotid stiffness, and regional aortic stiffness were measured, as was dp-ucMGP as well as acute phase markers for endothelial dysfunction.

***Results:***

- After three years of supplementation with MK-7, measures of aortic stiffness significantly decreased.
- Compared to placebo, MK-7 decreased dp-ucMGP by 50%, but did not influence the markers for acute phase and endothelial dysfunction.
- Researchers concluded that long-term supplementation with MK-7 improves arterial stiffness in healthy postmenopausal women, especially those with high arterial stiffness


**2. Detailed Pharmacokinetics [13]**

Long chain menaquinones have more complex disappearance curves with a long half-life. Uni-K2-7 remains detectable even at 72 hrs.

***Absorption:***

Menaquinones, which are primarily derived from animal-based sources, are consumed in food matrices containing more fat that may improve absorption and lead to higher bioavailability. The MK-7 (Uni-K2-7) data show peaks at 4 h after intake, but Uni-K2-7 does not appear to be completely removed from the circulation after 72–96 h.


Evidences demonstrate that serum vitamin K2 levels when compared after consecutive administration of MK-4 and Uni-K2-7 (60 µg/day) for 7 days; the baseline serum level of MK-4 was 2.2 ng/ml ± 0.38 and that of MK-7 was less than detection limit. After subtracting the baseline serum levels from all values, MK-4 levels were 0.00 ng/ml ± 0.77 and 0.03 ng/ml ± 0.27 in the MK-4 and Uni-K2-7-treated groups, respectively. While MK-4 intake did not increase MK-4 administered group, serum Uni-K2-7 increased significantly.



**Figure 4: Increased serum vitamin K2 levels in subjects after 7 days of consecutive administration (60 µg/day)**

***Storage and distribution [14]:***

Human liver stores normally comprise about 90 percent menaquinones. For plasma Uni-K2-7, a clear dose–response effect is seen on the circulating Uni-K2-7 concentrations after supplementation with doses ranging between 45 and 420 mg.



**Figure 5: Dose-response relationship between Uni-K2-7 intake and 24h-AUC circulating Uni-K2-7 values**

### **Metabolism**

The metabolites are formed from the most potent gamma-carboxylation activity. The metabolites formed are however safe and do not cause any adverse effects.

### **Elimination**

Vitamin K builds relatively low stores and circulation levels compared to vitamins A, D and E. Early isotopic work shows that regardless of dose, 45 mcg/day or 1mg/day, 60 to 70% of a single dose of Uni-K2-7 is ultimately excreted as catabolic products in the bile and urine.

### **3. Toxicology**

There is no known toxicity associated with high doses of Uni-K2-7. A point of concern is however the potential interference of K vitamins with OAC treatment: individuals taking anticoagulant medications, such as warfarin (coumarins), should consult their doctor before taking Uni-K2-7. Unlike the other fat-soluble vitamins, Uni-K2-7 is not stored in any significant quantity in the liver; therefore toxic level is not a described problem. All data available at this time demonstrate that Uni-K2-7 has no adverse effects in healthy subjects. The

recommendations for the daily intake of Uni-K2-7, as issued recently by the Institute of Medicine, also acknowledge the wide safety margin of Uni-K2-7.

There is no documented case of toxicity for Menaquinones. The European Food Safety Authority's safety assessment of menaquinones as a source of vitamin K added for nutritional purposes concluded that low doses of menaquinones presented no safety concerns. Similarly, an animal study reported no toxicity associated with synthetic Uni-K2-7 administered in a single oral dose up to 2000 mg/kg or for 90 d of oral administration of 10 mg/kg per day.

Vitamin K-dependent proteins have a limited number of Glu residues capable of  $\gamma$ -carboxylation per molecule, beyond which there can be no further  $\gamma$ -carboxylation or excessive coagulation. Despite this, it is critical to demonstrate that a high intake of menaquinones does not increase thrombosis risk.

#### **4. Important Studies and Observations**

[Vitamin K27 clinical trial for Diabetic Neuropathy \(PDF\)](#)

[AHA Vit K2 and anticoagulation \(PDF\)](#)

#### **5. Reference**

1. Collins MD, Jones D. Distribution of isoprenoid quinone structural types in bacteria and their taxonomic implication. *Microbiol Rev.* 1981; 45:316-354.
2. Suttie JW. Vitamin K and human nutrition. *J Am Diet Assoc.* 1992; 92:585-590.
3. Hosoi T. Clinical implications of under-carboxylated osteocalcin. *Clin Calcium* 2009; 19:1815-21.
4. Shearer MJ, Newman P. Metabolism and cell biology of vitamin K. *Thromb Haemost.* 2008; 100:530-547.
5. Sakagami H, Hashimoto K, Suzuki F, et al. Tumor-specificity and type of cell death induced by vitamin K2 derivatives and prenylalcohols. *Anticancer Res.* 2008; 28:151-158.
6. Luo G, Ducy P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. *Nature* 1997; 386:78-81.

7. Geleijnse JM, Vermeer C, Grobbee DE, et al. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. *J Nutr.* 2004; 134:3100-3105.
8. Margueritta S, Joseph J, Elias J. Vitamin K Dependent Proteins and the Role of Vitamin K2 in the Modulation of Vascular Calcification: A Review. *Oman Med J.* 2014; 29(3):172-177.
9. Steven M, Davis WL. Vitamin K2 in Bone Metabolism and Osteoporosis. *Altern Med Rev.* 2005; 10(1):24-35.
10. Johanna MG, Cees V, et al. Dietary Intake of Menaquinone Is Associated with a Reduced Risk of Coronary Heart Disease: The Rotterdam Study. *J. Nutr.* 134: 3100–3105, 2004.
11. Caluwé R1, Vandecasteele S2, et al. Vitamin K2 supplementation in haemodialysis patients: a randomized dose-finding study. *Nephrol Dial Transplant.* 2014; 29(7):1385-90.
12. Katarzyna M, Eugene JB. Vitamin K2: an essential protector for cardiovascular health. *Agro FOOD Industry Hi Tech.* 2015; 26(5): 21-24.
13. Toshiro S, Leon JS. Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy women. *Nutrition Journal* 2012, 11:93.
14. Knapen MH, Vermeer C, et al. Pharmacokinetics of Menaquinone-7 (Vitamin K2) in Healthy Volunteers. *J Clin Trials* 4: 160. doi:10.4172/2167-0870.1000160.
15. Joline WJ, Sarah L. The role of menaquinones (vitamin K2) in human health. *Brit J Nutr.* Page 1 of 12; doi:10.1017/S0007114513001013.

# A Novel Potential Role of Vitamin K2-7 in Relieving Peripheral Neuropathy

Dilip S. Mehta, Yogesh A. Dound<sup>1</sup>, Shashank S. Jadhav<sup>1</sup>, Abhay A. Bhave<sup>2</sup>, Milind Devale<sup>3</sup>, Ashok D. B. Vaidya<sup>4</sup>

Synergia Life Sciences Pvt. Ltd, <sup>1</sup>Department of Medical, Synergia Life Sciences Pvt. Ltd, <sup>2</sup>Empire Centre Haematology and Oncology Specialty Clinic, <sup>3</sup>Department of Medicine, Kokan Hospital, <sup>4</sup>Kasturba Health Society Medical Research Center, Mumbai, Maharashtra, India

## Abstract

**Objective:** To assess the efficacy, tolerability and safety of vitamin K2-7 in patients with peripheral neuropathy (PN). **Materials and Methods:** This study was conducted in 100 patients with PN suffering from VBD or T2DM. Vitamin K2-7 capsules (200 mcg) were given orally for 8 weeks followed up to the 12<sup>th</sup> week. Symptoms included tingling and numbness along with weakness, fatigue, and cramps. The intensity of the symptoms of PN was assessed on a Visual Analog Scale (VAS). **Results:** At baseline, the VAS score was 6–9 for VBD group and 8–10 for T2DM group. After treatment with Vitamin K2-7 by the 12<sup>th</sup> week, VAS score had reduced to 1–2 in both groups. The decrease was statistically significant ( $P < 0.0001$ ). **Conclusion:** For the first time, in larger sample size, it has been shown that Vitamin K2-7, 200 mcg for 8 weeks, has a therapeutic activity for the symptoms of PN in VBD and T2DM. The reduction in symptoms was persistent in spite of de-challenge of Vitamin K2-7. Vitamin K2-7 was also well tolerated by all the patients. Thus, it can be concluded that Vitamin K2-7 has potential therapeutic effects for PN due to VBD or T2DM.

**Keywords:** Peripheral neuropathy, type 2 diabetes mellitus, Vitamin B12 deficiency, Vitamin K2-7

## INTRODUCTION

Peripheral Neuropathy (PN) is a common problem faced by a large number of patients with its etiology being multifactorial. The most common among them could be Diabetes Mellitus (DM). Currently, 347 million people worldwide have diabetes.<sup>[1]</sup> India has the largest number of type 2 diabetic patients among the world diabetics. Increased prevalence globally or in India, DM has become a huge economic and health burden to the nation.<sup>[2]</sup> India is one of the epicenters of the global DM pandemic. Rapid social and economic development and changes in demography and also with increased susceptibility for Indian population have led to the increase in the prevalence of DM in India over the past four decades.<sup>[3]</sup>

Vitamin B<sub>12</sub> Deficiency (VBD) is often missed and is frequently neglected. There is a high incidence in the vegetarian population. The manifestations of neuropathy in these conditions vary from mild to severe with symptoms of sensory and motor defects, and it reduces the quality of life and productivity. The neurologic manifestations of folate

deficiency overlap with those of VBD and include cognitive impairment, dementia, depression, and commonly PN.<sup>[4]</sup>

One added cause of iatrogenic neuropathy in DM is the treatment with metformin that leads to VBD.<sup>[5]</sup> Persistence of neuropathy symptoms despite routine treatment is a well-identified unmet medical need.

The prevalence of symptoms of neuropathy in diabetic population in India is 26%–31%.<sup>[6]</sup> In an epidemiological survey conducted in India, based on a figure of about 40 million people with diabetes in India, it is estimated that there would be at least 10.4 million people suffering from symptoms of PN.<sup>[7]</sup> Long-term therapy with metformin is shown to decrease the Vitamin B12 level and manifested as PN.<sup>[8]</sup> In spite of treatment with Vitamin B12 supplements, the symptoms of neuropathy

**Address for correspondence:** Yogesh A. Dound, Synergia Life Sciences Pvt. Ltd., 6/312, Jogani Industrial Complex, V N Purav Marg, Chunabhatti, Mumbai - 400 022, Maharashtra, India. E-mail: [yogesh\\_dound@yahoo.com](mailto:yogesh_dound@yahoo.com)

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

**For reprints contact:** [reprints@medknow.com](mailto:reprints@medknow.com)

**How to cite this article:** Mehta DS, Dound YA, Jadhav SS, Bhave AA, Devale M, Vaidya AD. A novel potential role of Vitamin K2-7 in relieving peripheral neuropathy. *J Pharmacol Pharmacother* 2018;9:180-5.

**Received:** 13-06-2018 **Revised:** 28-10-2018 **Accepted:** 12-12-2018

## Access this article online

Quick Response Code:



Website:  
[www.jpharmacol.com](http://www.jpharmacol.com)

DOI:  
10.4103/jpp.JPP\_72\_18

will still be persistent. The same trend is seen in Vitamin B12-deficient patients, where the neuropathy symptoms are persistent despite Vitamin B12 supplementation. This is an observation of an expert hematologist (AAB) which he termed as residual neuropathy.

Two of the authors (DSM and ABV) of the present study had earlier observed that Vitamin K2-7 relieves idiopathic muscle cramps as well as symptoms of diabetic neuropathy.<sup>[9]</sup> PCT/IN2008/000465, application further claims the safety of usage of Vitamin K2-7 in the various novel conditions such as neuropathy.<sup>[10]</sup> It was found by anecdotal observation that Vitamin K2-7 helps in relieving neuropathy.

Taking a lead from this serendipitous discovery, it was decided to conduct an open-labeled study of Vitamin K2-7 (MK-7) in 30 patients of PN suffering from VBD and/or type 2 DM (T2DM) in 2009. The study was conducted at BYL Nair Ch. Hospital, Mumbai, and it was shown that Vitamin K2-7 at a dose of 100 mcg twice a day for 8 weeks was well tolerated and safe with a therapeutic activity for relieving the symptoms of PN.<sup>[11]</sup>

Based on the results of the above study, a larger cohort study was planned to evaluate and confirm the efficacy, tolerability, and safety of Vitamin K2-7 in patients with PN experienced by patients of VBD and T2DM.

## MATERIALS AND METHODS

### Study design

An open-labeled observational study for evaluation of efficacy and tolerability of Vitamin K2-7 (MK-7) in patients of T2DM or VBD with PN after approval of the Independent Ethics Committee, Intersystem BioMedica Ethics Committee (ISBEC/NR-14/KM/VM/2015), Vile Parle, Mumbai, was conducted. The trial was registered with the Clinical Trial Registry of India (CTRI) (CTRI/2016/11/007499). Patients were recruited from the Medicine Department of Kokan Hospital, Jogeshwari, Mumbai, India. Patients satisfying the following inclusion and exclusion criteria were enrolled in the study.

The inclusion criteria of this study were as follows: male or female aged 18–65 years suffering from T2DM or VBD with symptomatic diagnosis of neuropathy (>4 on Visual Analog Scale [VAS] score) and willing to give informed consent. The exclusion criteria of this study were as follows: patients suffering from any other illness other than T2DM or VBD, patient participation in clinical trials evaluating investigational pharmaceuticals or biologics within 3 months or admission to study, patients under medications such as corticosteroids and oral contraceptives, patients with seropositive status, pregnancy, patients on coumarin analogs and quinine hydrochloride, and patients who are under history of alcohol and substance abuse within previous 1 year. The primary outcomes were activity and tolerability of Vitamin K2-7 in patients with symptoms of PN suffering from T2DM or VBD

as measured on VAS. The secondary outcomes were clinical and metabolic variables.

### Study procedure

Patients suffering from PN symptoms due to T2DM or VBD and those found meeting inclusion criteria were enrolled in the study. A written informed consent (informed consent form approved by the Ethics Committee) was obtained from all the patients. Participant confidentiality was maintained throughout the study. After enrollment, the data regarding age, gender, diagnosis, treatment history, and baseline clinical laboratory investigations were recorded in the case record form (approved by the Ethics Committee).

After a proper history, examination and investigations, patients were selected as per the inclusion criteria mentioned in the protocol. Blood investigations, namely complete blood counts with Erythrocyte Sedimentation Rate (ESR), Vitamin B-12, homocysteine, glycosylated hemoglobin, fasting and postprandial plasma glucose, Prothrombin Time (PT)-international normalized ratio, liver function tests, and renal function tests were done at the baseline, at the 4<sup>th</sup> week, and at the end of the study. The patients were assessed at follow-ups at the end of the 1<sup>st</sup>, 2<sup>nd</sup>, 4<sup>th</sup>, 6<sup>th</sup>, 8<sup>th</sup>, and 12<sup>th</sup> weeks. A detailed physical (general and systemic) examination was done at the baseline and at every visit. The ambulant patients were given 2 capsules (100 mcg each) a day of Vitamin K2-7 for 8 weeks and followed up to 12<sup>th</sup> week. The subjective severity of the symptoms of PN was assessed with validated VAS scale from 0 to 10 (nil to unbearable) at baseline and thereafter every week till the end of the 12<sup>th</sup> week. This scale has been used in various studies to measure the intensity and severity of various symptoms of neuropathy.<sup>[12]</sup> This score was recorded in a patient diary (approved by the Ethics Committee). The safety was assessed by clinical tolerability, side effects, and adverse events and by any change in the organ function tests. The therapeutic activity was assessed by noting the reduction in the severity of the symptoms of PN, namely tingling and numbness along with weakness, fatigue, and cramps as compared to the baseline. Any other effect during the therapy – beneficial or adverse – was also recorded.

Complete blood counts were done by the PC 210 ERMA blood cell counter. ESR was done by Wintrobe method. Liver function test and renal function test were done by biochemical method. PT was done by coagulation method. Fasting and postprandial plasma glucose was estimated by GOD-POD enzymatic method. Glycosylated hemoglobin was measured by boronate affinity method on NycoCard. Vitamin B-12 and homocysteine were done by RIA/ELISA/CLIA method.

Vitamin K2-7 was supplied by Synergia Life Sciences Pvt. Ltd., in the form of capsules (100 mcg) packed 30 capsules per bottle. The capsules were supplied in bottles to patients at the time of the enrollment and at an interval of every 15 days. A patient ingested a 100 mcg capsule every morning

immediately after breakfast and immediately after dinner for 8 weeks. The drug compliance was judged by counting the capsules in the bottle brought back at the follow-up visits. The patient was said to be compliant if he had consumed minimum 80% of the total dispensed capsules.

Vitamin K2-7 capsules were clinically tolerated well by all the patients. Five mild adverse events were reported, which were said to be unrelated to the test substance as judged by the principal investigator. No serious adverse events were reported during the period of therapy. Biochemical investigations and the organ function tests were in normal limits at the baseline, at the 4<sup>th</sup> week, at the 8<sup>th</sup> week, and at the end of the 12<sup>th</sup> week.

### Statistical analysis

The statistical analysis of the VAS score was done by one-way analysis of variance test using the Statistical Package of the Social Science (SPSS) version 11.0 (SPSS Inc., Chicago, IL, USA).

## RESULTS

One hundred and seven patients aged 18–60 years were screened. Out of 107 patients, 100 patients completed the study [Figure 1]. The baseline data of the two groups were comparable with respect to demographic data and clinical variables of patients with PN [Table 1].




Figure 1: Study flowchart

Patients from VBD group had VAS score of 6–9 at baseline and patients from T2DM group had VAS score of 8–10 at baseline.

By the end of the 4<sup>th</sup> week, after taking Vitamin K2-7 (200 mcg/day), the VAS score in VBD group had reduced to 4–7 and the VAS score in T2DM group had reduced to 6–8. There was a reduction in the intensity of the symptoms of tingling and numbness. Patients had started experiencing better with the therapy. The associated conditions such as weakness and fatigue had also reduced. Patients, who had also complained of cramps, had reduced number of cramps. The intensity of cramps in VBD patients and burning pain in T2DM patients had reduced to a greater extent.

By the end of 8 weeks after giving Vitamin K2-7 (200 mcg/day), the VAS score in VBD group had reduced to 3–5 and the VAS score in T2DM group had reduced to 2–5. The tingling and numbness had reduced significantly. There was a significant decrease in weakness and fatigue. Cramps and burning pain were now occasional with decreased intensity. By the end of the 12<sup>th</sup> week, the VAS score of 1–2 in VBD group as well as in T2DM group indicated a continued relief in the symptoms of PN. Decrease in VAS Score of symptomatology in VBD group and T2DM group are graphically represented. There was a decrease in VAS score of individual symptoms of PN from baseline to the 12<sup>th</sup> week in VBD group and T2DM group [Table 2]. Data of T2DM group were found to be statistically significant. Data of VBD group were found to be statistically significant.

During the period of trial, patients were advised to refrain from any other medications which will have a potential impact on PN.

## DISCUSSION

PN is a global health concern without adequate therapeutic approach. It causes difficulties in daily activities, decreases performance, and increases health-care costs.<sup>[13]</sup> The most common cause is vitamin deficiencies such as Vitamin B12 and disease conditions such as DM. Other causes are autoimmune disorders, alcohol, heavy metal toxicity, and anticancer

**Table 1: Baseline demographic data and clinical variables of patients with peripheral neuropathy**

	Vitamin B <sub>12</sub> deficiency	Type 2 diabetes mellitus
Number of patients (n)	47	53
Age (years)	45.36 (8.94)	45.19 (9.04)
Gender		
Men	21	30
Women	26	23
Vitamin B <sub>12</sub> (pg/ml)	198.30 (48.17)	397.92 (119.44)
Blood sugar (mg/dl)		
Fasting	90.98 (9.36)	156.92 (47.13)
Postprandial	114.31 (7.20)	222.88 (15.03)

Values are expressed in mean (SD). SD=Standard deviation

**Table 2: Decrease in visual analog scale score of individual symptoms of peripheral neuropathy from baseline to the 12<sup>th</sup> week in Vitamin B12 deficiency group and type 2 diabetes mellitus group**

	Vitamin B <sub>12</sub> deficiency (n=47)	Type 2 diabetes mellitus (n=53)		
	Baseline	12 <sup>th</sup> week	Baseline	12 <sup>th</sup> week
Tingling	8.21 (0.657)	1.68 (0.663)*	8.40 (0.716)	1.91 (0.904)*
Pricking sensation	8.04 (1.370)	1.64 (0.705)*	8.40 (0.716)	1.91 (0.904)*
Burning pain	0.98 (2.680)	0.20 (0.571)*	7.62 (2.350)	1.75 (0.918)*
Cramps	9.06 (12.200)	1.51 (0.777)*	1.81 (3.300)	0.55 (1.290)*

Values are expressed as mean(SD). SD=Standard deviation. \*P<0.0001- statistically significant

medicines. India, with huge vegetarian population and load of Diabetes epidemic has a huge number of patients affected by PN.

The most common symptoms of PN are tingling, numbness, weakness, tiredness, heaviness, pain, itching, crawling, cramps, muscle twitching tremor, gait abnormality, and sensation of pins and needles.

VBD, a leading cause of neuropathy, of mild-to-moderate nature is often missed and is relatively neglected. It has a high incidence in vegetarian population because of lack of Vitamin B12 intake.<sup>[14]</sup> The diagnosis of neuropathy due to VBD remains a real challenge for the clinician.

In case of DM, another leading cause of neuropathy, vascular complications are well recognized and account for mortality and morbidity. As a result, there is a rapidly increasing interest in searching new therapeutics or even better searching prophylactic methods. Based on a large number of chemical and pharmacological research work, numerous bioactive compounds have been found, especially in functional food ingredients for diabetes.<sup>[15]</sup> Musculoskeletal manifestations of diabetes are common and, though not life threatening, are an important cause of morbidity, pain, and disability. The burden from painful diabetic PN appears to be higher with increasing severity of pain. More severe pain leads to a higher impairment in daily functioning, sleep, and health-related quality of life.<sup>[16]</sup> Health-related quality of life is increasingly viewed as a therapeutic outcome and is gradually gaining the same level of importance as clinical or physiological outcome parameters in T2DM patients.<sup>[17]</sup>

India has the second largest number of people with T2DM in the world (~69 million individuals as of 2015).<sup>[18]</sup> Diabetic neuropathy continues to represent a therapeutic challenge as the pain relief is still unsatisfactory.<sup>[19]</sup> The pharmacological treatments are symptomatic, not focused on the pathophysiological mechanisms, limited by side effects and by the development of tolerance.<sup>[20]</sup> Persistence of neuropathy symptoms despite treatment makes it an unmet medical need.

A higher prevalence of PN is observed in known T2DM patients 33.7% (95% confidence interval: 31.42–36.01).<sup>[21]</sup> In a cross-sectional study by Roy *et al.*,<sup>[8]</sup> the authors have shown that metformin users even for 2 years showed evidence of neuropathy on nerve conduction velocity though their body mass index and postprandial blood sugar were maintained.

It is interesting to know that Vitamin K2-7 also plays a role in the prevention and control of T2DM.<sup>[22]</sup> Vitamin K2-7 plays a role in carboxylating osteocalcin, a Vitamin K-dependent protein, which has been shown to regulate the glucose homeostasis.<sup>[23]</sup>

A decade-long study of 38,094 Dutch population aged 20–70 found that the participants who consumed the most dietary Vitamin K were 20% less likely to develop type 2 diabetes than the participants with the lowest intake of Vitamin K.<sup>[22]</sup> Vitamin K2 is linked to lowered risk of developing type 2 diabetes. The risk of developing type 2 diabetes drops for every 10 mcg increase in Vitamin K2 intake. In this study, participants with the highest intake of K2 consumed 250–360 mcg/day. Thus, higher intake of Vitamin K2 is linked to lower diabetes risk.

It is also known that Vitamin K2-7 reduces the progression of insulin resistance and improves insulin sensitivity.<sup>[24]</sup> In an attempt to better understand how Vitamin K2 improves insulin sensitivity, researchers from Seoul National University, South Korea, studied 42 healthy male volunteers. Participants were either given 30,000 mcg of Vitamin K2 or a placebo each day for 4 weeks. Vitamin K2 supplementation significantly increased insulin sensitivity and seemed to be related to increased carboxylation (activation) of osteocalcin. Researchers concluded that Vitamin K2 can help regulate glucose metabolism by activating osteocalcin, an endocrine hormone that increases insulin sensitivity in humans.<sup>[25]</sup>

One of the common complications of diabetes is cardiovascular diseases. It is the leading cause of diabetes-related deaths. Heart disease is two to four times more common in population with diabetes.<sup>[26]</sup> Vitamin K2-7 plays role in carboxylating matrix Gla protein, a known inhibitor of arterial calcification. It helps in keeping calcium out of the arteries and also supports cardiovascular health.<sup>[27]</sup> This has been covered by Rotterdam Study<sup>[28]</sup> and Gast Study.<sup>[29]</sup> Hence, it is now clear that Vitamin K2-7 has a multifactorial role in the human physiology. The research has moved forward from “Glu-Gla” physiology to disease mechanistic approaches such as redox cycle (unpublished data by Synergia Life Sciences), which can effectively address the underlying mechanism of Vitamin K2-7 and its therapeutic effects in various unrelated areas such as cramps and neuropathy.

To further evaluate the potential role of Vitamin K2-7 in other related disease conditions such as cramps, an open-labeled observation trial was carried out by Mehta *et al.*<sup>[9]</sup> It was

observed that Vitamin K2-7 effectively ameliorated the symptoms of idiopathic muscle cramps. Toxicity studies conducted by Ravishankar *et al.* have shown that Vitamin K2-7 is nontoxic up to dose of 20,000 mg.<sup>[30]</sup>

## CONCLUSION

It can be effectively concluded from the current study that Vitamin K2-7 at a dose of 100 mcg twice a day for 8 weeks was found to be well tolerated and has a potential for relief of symptoms of PN in cases of VBD and T2DM. It also helps in relieving the associated symptoms of PN such as cramps, burning pain, weakness, and fatigue. It can be concluded that even after the discontinuation of Vitamin K2-7, the symptoms of neuropathy continued to remain with reduced intensity and severity. This proves the therapeutic potential of Vitamin K2-7. More research is ongoing to identify the mechanistic approach of Vitamin K2-7. Till then, clinical studies such as the current study conducted show the promise of Vitamin K2-7 in PN, especially residual neuropathy which is an unmet need. Vitamin K2-7 offers a confirming therapeutic effect in the PN as shown by this study. Further, a multicentric placebo-controlled randomized double-blind trial can clearly establish the effect of Vitamin K2-7.

## Acknowledgment

We thankfully acknowledge the inputs of Dr. Rama Vaidya, Director, Division of Endocrine and Metabolic Disorders, Medical Research Center, Kasturba Health Society, in the preparation of the manuscript of the published article. We thank Dr. Arun Arote for the laboratory evaluation of biochemical and organ function tests. We would also like to thank Mr. Himanshu Sankrityayan from SPP School of Pharmacy and Technology Management, SVKM's NMIMS, Mumbai, for the statistical analysis of the data. We appreciate the guidance and technical expertise of Dr. Anselm de Souza, Director, Synergia Life Sciences Pvt. Ltd.

## Financial support and sponsorship

Nil.

## Conflicts of interest

There are no conflicts of interest.

## REFERENCES

- Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. *Diabetes Care* 2004;27:1047-53.
- Ramachandran A. Socio-economic burden of diabetes in India. *J Assoc Physicians India* 2007;55 Suppl:9-12.
- Unnikrishnan R, Anjana RM, Mohan V. Diabetes mellitus and its complications in India. *Nat Rev Endocrinol* 2016;12:357-70.
- Reynolds EH. The neurology of folic acid deficiency. *Handb Clin Neurol* 2014;120:927-43.
- Wulffelé MG, Kooy A, Lehert P, Bets D, Ogtrop JC, Borger van der Burg B, *et al.* Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and Vitamin B12 in type 2 diabetes mellitus: A randomized, placebo-controlled trial. *J Intern Med* 2003;254:455-63.
- Pradeepa R, Rema M, Vignesh J, Deepa M, Deepa R, Mohan V, *et al.* Prevalence and risk factors for diabetic neuropathy in an urban South Indian population: The Chennai urban rural epidemiology study (CURES-55). *Diabet Med* 2008;25:407-12.
- Joshi SR. Diabetes care in India. *Ann Glob Health* 2015;81:830-8.
- Roy RP, Ghosh K, Ghosh M, Acharyya A, Bhattacharya A, Pal M, *et al.* Study of Vitamin B<sub>12</sub> deficiency and peripheral neuropathy in metformin-treated early type 2 diabetes mellitus. *Indian J Endocrinol Metab* 2016;20:631-7.
- Mehta DS, Vaidya RA, Dound YA, Nabar NS, Pandey SN, Vaidya AD. Therapeutic activity and safety of Vitamin K2-7 in muscle cramps: An interventional case-series. *TIP* 2010;63:287-91.
- Vaidya AB, Mehta DS, de' Souza A, Vaidya RA, inventors. Viridis BioPharma Pvt. Ltd., assignee. Treatment using Vitamin K Analogs and Derivatives. Australian Patent 2008322224. 2012-05-10.
- Kulkarni VK, Upase DP, Dound YD, Jadhav SS, Bhave AS, Mehta DS, *et al.* The effect of Vitamin K2-7 in peripheral neuropathy due to Vitamin B12 deficiency and diabetes mellitus: A preliminary study. *TIP* 2013;66:625-9.
- Daswani PG, Ghokal MS, Birdi TJ. *Psidium guajava*: A single plant for multiple health problems of rural Indian population. *Pharmacogn Rev* 2017;11:167-74.
- Raafat K, El-Haj R, Shoumar D, Alaaeddine R, Fakhro Y, Tawil N, *et al.* Neuropathic pain: Literature review and recommendations of potential phytotherapies. *Pharmacogn J* 2017;9:424-34.
- Oosterhuis WP, Niessen RW, Bossuyt PM, Sanders GT, Sturk A. Diagnostic value of the mean corpuscular volume in the detection of Vitamin B12 deficiency. *Scand J Clin Lab Invest* 2000;60:9-18.
- Perera PK, Li Y. Functional herbal food ingredients used in type 2 diabetes mellitus. *Pharmacogn Rev* 2012;6:37-45.
- Alleman CJ, Westerhout KY, Hensen M, Chambers C, Stoker M, Long S, *et al.* Humanistic and economic burden of painful diabetic peripheral neuropathy in Europe: A review of the literature. *Diabetes Res Clin Pract* 2015;109:215-25.
- Puvvada RC, Muthukumar VA. Impact of patient counselling on the knowledge, attitude, practice and quality of life in patients with hypertension with diabetes mellitus-II. *Indian J Pharm Educ Res* 2018;52:305-10.
- International Diabetes Federation. IDF Diabetes Atlas. 7<sup>th</sup> ed. Brussels, Belgium: International Diabetes Federation; 2015.
- Schreiber AK, Nones CF, Reis RC, Chichorro JG, Cunha JM. Diabetic neuropathic pain: Physiopathology and treatment. *World J Diabetes* 2015;6:432-44.
- Boyle J, Eriksson ME, Gribble L, Gouni R, Johnsen S, Coppini DV, *et al.* Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: Impact on pain, polysomnographic sleep, daytime functioning, and quality of life. *Diabetes Care* 2012;35:2451-8.
- Bansal D, Gudala K, Muthyalu H, Esam HP, Nayakallu R, Bhansali A. Prevalence and risk factors of development of peripheral diabetic neuropathy in type 2 diabetes mellitus in a tertiary care setting. *J Diabetes Investig* 2014;5:714-21.
- Yoshida M, Jacques PF, Meigs JB, Saltzman E, Shea MK, Gundberg C, *et al.* Effect of Vitamin K supplementation on insulin resistance in older men and women. *Diabetes Care* 2008;31:2092-6.
- Vella A, Kumar R. Osteocalcin and the regulation of glucose metabolism. *Clin Rev Bone Miner Metab* 2013;11:11-6.
- Beulens JW, van der A DL, Grobbee DE, Sluijs I, Spijkerman AM, van der Schouw YT, *et al.* Dietary phylloquinone and menaquinones intakes and risk of type 2 diabetes. *Diabetes Care* 2010;33:1699-705.
- Choi HJ, Yu J, Choi H, An JH, Kim SW, Park KS, *et al.* Vitamin K2 supplementation improves insulin sensitivity via osteocalcin metabolism: A placebo-controlled trial. *Diabetes Care* 2011;34:e147.
- Welborn T. Diabetes mortality. In: Ekoe JM, Zimmet P, Williams R, editors. *The Epidemiology of Diabetes Mellitus: An International Perspective*. Chichester, United Kingdom: John Wiley and Sons Ltd.;

Mehta, *et al.*: Role of Vitamin K2-7 in relieving peripheral neuropathy


2001. p. 369-82.

27. Price PA, Otsuka AA, Poser JW, Kristaponis J, Raman N. Characterization of a gamma-carboxyglutamic acid-containing protein from bone. *Proc Natl Acad Sci U S A* 1976;73:1447-51.

28. Geleijnse JM, Vermeer C, Grobbee DE, Schurgers LJ, Knapen MH, van der Meer IM, *et al.* Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: The Rotterdam study. *J Nutr* 2004;134:3100-5.

29. Gast GC, de Roos NM, Sluijs I, Bots ML, Beulens JW, Geleijnse JM, *et al.* A high menaquinone intake reduces the incidence of coronary heart disease. *Nutr Metab Cardiovasc Dis* 2009;19:504-10.

30. Ravishankar B, Dound YA, Mehta DS, Ashok BK, de Souza A, Pan MH, *et al.* Safety assessment of menaquinone-7 for use in human nutrition. *J Food Drug Anal* 2015;23:99-108.



## American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy

Jack Hirsh, MD, FRCP(C), FRACP, FRSC, DSc; Valentin Fuster, MD, PhD;  
Jack Ansell, MD; Jonathan L. Halperin, MD

### Pharmacology of Warfarin

#### Mechanism of Action of Coumarin

##### Anticoagulant Drugs

Warfarin, a coumarin derivative, produces an anticoagulant effect by interfering with the cyclic interconversion of vitamin K and its 2,3 epoxide (vitamin K epoxide). Vitamin K is a cofactor for the carboxylation of glutamate residues to  $\gamma$ -carboxyglutamates (Gla) on the N-terminal regions of vitamin K-dependent proteins (Figure 1) (1–6). These proteins, which include the coagulation factors II, VII, IX, and X, require  $\gamma$ -carboxylation by vitamin K for biological activity. By inhibiting the vitamin K conversion cycle, warfarin induces hepatic production of partially decarboxylated proteins with reduced coagulant activity (7,8).

Carboxylation promotes binding of the vitamin K-dependent coagulation factors to phospholipid surfaces, thereby accelerating blood coagulation (9–11).  $\gamma$ -Carboxylation requires the reduced form of vitamin K (vitamin KH<sub>2</sub>). Coumarins block the formation of vitamin KH<sub>2</sub> by inhibiting the enzyme vitamin K epoxide reductase, thereby limiting the  $\gamma$ -carboxylation of the vitamin K-dependent coagulant proteins. In addition, the vitamin K antagonists inhibit carboxylation of the regulatory anticoagulant proteins C and S. The anticoagulant effect of coumarins can be overcome by low doses of vitamin K<sub>1</sub> (phytonadione) because vitamin K<sub>1</sub> bypasses vitamin K epoxide reductase (Figure 1). Patients treated with large doses of vitamin K<sub>1</sub> (usually >5 mg) can become resistant to warfarin for up to a week because vitamin K<sub>1</sub> accumulating in the liver is available to bypass vitamin K epoxide reductase.

Warfarin also interferes with the carboxylation of Gla proteins synthesized in bone (12–15). Although these effects contribute to fetal bone abnormalities when mothers are treated with warfarin during pregnancy (16,17), there is no evidence that warfarin directly affects bone metabolism when administered to children or adults.

### Pharmacokinetics and Pharmacodynamics of Warfarin

Warfarin is a racemic mixture of 2 optically active isomers, the R and S forms, in roughly equal proportion. It is rapidly absorbed from the gastrointestinal tract, has high bioavailability (18,19), and reaches maximal blood concentrations in healthy volunteers 90 minutes after oral administration (18,20). Racemic warfarin has a half-life of 36 to 42 hours (21), circulates bound to plasma proteins (mainly albumin), and accumulates in the liver, where the 2 isomers are metabolically transformed by different pathways (21). The relationship between the dose of warfarin and the response is influenced by genetic and environmental factors, including common mutations in the gene coding for cytochrome P450, the hepatic enzyme responsible for oxidative metabolism of the warfarin S-isomer (18,19). Several genetic polymorphisms in this enzyme have been described that are associated with lower dose requirements and higher bleeding complication rates compared with the wild-type enzyme CYP2C9\* (22–24).

In addition to known and unknown genetic factors, drugs, diet, and various disease states can interfere with the response to warfarin.

The anticoagulant response to warfarin is influenced both by pharmacokinetic factors, including drug interactions that affect its absorption or metabolic clearance, and by pharmacodynamic factors, which alter the hemostatic response to given concentrations of the drug. Variability in anticoagulant response also results from inaccuracies in laboratory testing, patient noncompliance, and miscommunication between the patient and physician. Other drugs may influence the pharmacokinetics of warfarin by reducing gastrointestinal absorption or disrupting metabolic clearance. For example, the anticoagulant effect of warfarin is reduced by cholestyramine, which impairs its absorption, and is potentiated by drugs that inhibit warfarin clearance through stereoselective or nonselective pathways (25,26). Stereoselective interactions may

---


The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.

This statement has been co-published in the April 1, 2003, issue of *Circulation*.

This statement was approved by the American Heart Association Science Advisory and Coordinating Committee in October 2002 and by the American College of Cardiology Board of Trustees in February 2003. A single reprint is available by calling 800-242-8721 (US only) or writing the American Heart Association, Public Information, 7272 Greenville Ave, Dallas, TX 75231-4596. Ask for reprint No. 71-0254. To purchase additional reprints: up to 999 copies, call 800-611-6083 (US only) or fax 413-665-2671; 1000 or more copies, call 410-528-4426, fax 410-528-4264, or e-mail [klbradle@lww.com](mailto:klbradle@lww.com). To make photocopies for personal or educational use, call the Copyright Clearance Center, 978-750-8400.

(*J Am Coll Cardiol* 2003;41:1633–52.)

©2003 by the American Heart Association, Inc, and the American College of Cardiology Foundation.



1. KO - reductase - warfarin sensitive
2. K - reductase - relatively warfarin resistant

**Figure 1.** The vitamin K cycle and its link to carboxylation of glutamic acid residues on vitamin K-dependent coagulation proteins. Vitamin K<sub>1</sub> obtained from food sources is reduced to vitamin K<sub>H2</sub> by a warfarin-resistant vitamin K reductase. Vitamin K<sub>H2</sub> is then oxidized to vitamin K epoxide (Vit KO) in a reaction that is coupled to carboxylation of glutamic acid residues on coagulation factors. This carboxylation step renders the coagulation factors II, VII, IX, and X and the anticoagulant factors protein C and protein S functionally active. Vit KO is then reduced to Vit K<sub>1</sub> in a reaction catalyzed by vitamin K reductase. By inhibiting vitamin K reductase, warfarin blocks the formation of vitamin K<sub>1</sub> and vitamin K<sub>H2</sub>, thereby removing the substrate (vitamin K<sub>H2</sub>) for the carboxylation of glutamic acids. Vitamin K<sub>1</sub>, either given therapeutically or derived from food sources, can overcome the effect of warfarin by bypassing the warfarin-sensitive vitamin K reductase step in the formation of vitamin K<sub>H2</sub>.

affect oxidative metabolism of either the S- or R-isomer of warfarin (25,26). Inhibition of S-warfarin metabolism is more important clinically because this isomer is 5 times more potent than the R-isomer as a vitamin K antagonist (25,26). Phenylbutazone (27), sulfinpyrazone (28), metronidazole (29), and trimethoprim-sulfamethoxazole (30) inhibit clearance of S-warfarin, and each potentiates the effect of warfarin on the prothrombin time (PT). In contrast, drugs such as cimetidine and omeprazole, which inhibit clearance of the R-isomer, potentiate the PT only modestly in patients treated with warfarin (26,29,31). Amiodarone inhibits the metabolic clearance of both the S- and R-isomers and potentiates warfarin anticoagulation (32). The anticoagulant effect is inhibited by drugs like barbiturates, rifampicin, and carbamazepine, which increase hepatic clearance (31). Chronic alcohol consumption has a similar potential to increase the clearance of warfarin, but ingestion of even relatively large amounts of wine has little influence on PT in subjects treated with warfarin (33). For a more thorough discussion of the effect of enzyme induction on warfarin therapy, the reader is referred to a recent critical review (34).

Warfarin pharmacodynamics are subject to genetic and environmental variability as well. Hereditary resistance to warfarin occurs in rats as well as in human beings (35-37), and patients with genetic warfarin resistance require doses 5-

to 20-fold higher than average to achieve an anticoagulant effect. This disorder is attributed to reduced affinity of warfarin for its hepatic receptor.

A mutation in the factor IX propeptide that causes bleeding without excessive prolongation of PT also has been described (38). The mutation occurs in <1.5% of the population. Patients with this mutation experience a marked decrease in factor IX during treatment with coumarin drugs, and levels of other vitamin K-dependent coagulation factors decrease to 30% to 40%. The coagulopathy is not reflected in the PT, and therefore, patients with this mutation are at risk of bleeding during warfarin therapy (38-40). An exaggerated response to warfarin among the elderly may reflect its reduced clearance with age (41-43).

Subjects receiving long-term warfarin therapy are sensitive to fluctuating levels of dietary vitamin K (44,45), which is derived predominantly from phylloquinones in plant material (45). The phylloquinone content of a wide range of foodstuffs has been listed by Sadowski and associates (46). Phylloquinones counteract the anticoagulant effect of warfarin because they are reduced to vitamin K<sub>H2</sub> through the warfarin-insensitive pathway (47). Important fluctuations in vitamin K intake occur in both healthy and sick subjects (48). Increased intake of dietary vitamin K sufficient to reduce the anticoagulant response to warfarin (44) occurs in patients consuming green vegetables or vitamin K-containing supplements while following weight-reduction diets and in patients treated with intravenous vitamin K supplements. Reduced dietary vitamin K<sub>1</sub> intake potentiates the effect of warfarin in sick patients treated with antibiotics and intravenous fluids without vitamin K supplementation and in states of fat malabsorption. Hepatic dysfunction potentiates the response to warfarin through impaired synthesis of coagulation factors. Hypermetabolic states produced by fever or hyperthyroidism increase warfarin responsiveness, probably by increasing the catabolism of vitamin K-dependent coagulation factors (49,50). Drugs may influence the pharmacodynamics of warfarin by inhibiting synthesis or increasing clearance of vitamin K-dependent coagulation factors or by interfering with other pathways of hemostasis. The anticoagulant effect of warfarin is augmented by the second- and third-generation cephalosporins, which inhibit the cyclic interconversion of vitamin K (51,52); by thyroxine, which increases the metabolism of coagulation factors (50); and by clofibrate, through an unknown mechanism (53). Doses of salicylates >1.5 g per day (54) and acetaminophen (55) also augment the anticoagulant effect of warfarin, possibly because these drugs have warfarin-like activity (56). Heparin potentiates the anticoagulant effect of warfarin but in therapeutic doses produces only slight prolongation of the PT.

Drugs such as aspirin (57), nonsteroidal antiinflammatory drugs (58), penicillins (in high doses) (59,60), and moxolactam (52) increase the risk of warfarin-associated bleeding by inhibiting platelet function. Of these, aspirin is the most important because of its widespread use and prolonged effect (61). Aspirin and nonsteroidal antiinflammatory drugs also can produce gastric erosions that increase the risk of upper gastrointestinal bleeding. The risk of clinically important bleeding is heightened when high doses of aspirin are taken

**TABLE 1. Capillary Whole Blood (Point-of-Care) PT Instruments**

Instrument	Clot Detection Methodology	Type of Sample	Home Use Approval
Protim Monitor 1000	Clot initiation: Thromboplastin	Capillary WB	No
Coumatrak*	Clot detection: Cessation of blood flow through capillary channel	Venous WB	
Ciba Corning 512 Coagulation Monitor*			
CoaguChek Plus*			
CoaguChek Pro*			
CoaguChek Pro/DM*			
CoaguChek	Clot initiation: Thromboplastin	Capillary WB	Yes†
CoaguChek S	Clot detection: Cessation of movement of iron particles	Venous WB Plasma	(CoaguChek only)
Thrombolytic Assessment System			
Rapidpoint Coag			
ProTIME Monitor	Clot initiation: Thromboplastin	Capillary WB	Yes
Hemochron Jr‡	Clot detection: Cessation of blood flow through capillary channel	Venous WB	
GEM PCL‡			
Avosure Pro+§	Clot initiation: Thromboplastin	Capillary WB	Yes
Avosure Pro§	Clot detection: Thrombin generations detected by fluorescent thrombin probe	Venous WB Plasma	
Avosure PT§			
Harmony	Clot initiation: Thromboplastin	Capillary WB	Yes
	Clot detection: Cessation of blood flow through capillary channel	Venous WB	
INRatio	Clot initiation: Thromboplastin	Capillary WB	Yes
	Clot detection: Change in impedance in sample	Venous WB	

WB indicates whole blood.

\*All instruments in this category are based on the original Biotrack model (Protim Monitor 1000) and licensed under different names. The latest version available is the CoaguChek Pro and Pro/DM (as models evolved, they acquired added capabilities); earlier models are no longer available.

†CoaguChek not actively marketed for home use at the time of this writing. Thrombolytic Assessment System not available for home use.

‡Hemochron Jr and GEM PCL are simplified versions of the ProTIME Monitor.

§Avosure instruments removed from market when manufacturer (Avocet, Inc) ceased operations (2001). Technology has since been purchased by Beckman Coulter.

||INRange system manufactured by Hemosense, Inc, is currently in development.

during high-intensity warfarin therapy (international normalized ratio [INR] 3.0 to 4.5) (57,62). In 2 studies, one involving patients with prosthetic heart valves (63) and the other involving asymptomatic individuals at high risk of coronary artery disease (64), low doses of aspirin (100 mg and 75 mg daily, combined with moderate- and low-intensity warfarin anticoagulation, respectively) also were associated with increased rates of minor bleeding.

The mechanisms by which erythromycin (65) and some anabolic steroids (66) potentiate the anticoagulant effect of warfarin are unknown. Sulfonamides and several broad-spectrum antibiotic compounds may augment the anticoagulant effect of warfarin in patients consuming diets deficient in vitamin K by eliminating bacterial flora and aggravating vitamin K deficiency (67).

Wells et al (68) critically analyzed reports of possible interactions between drugs or foods and warfarin. Interactions were categorized as highly probable, probable, possible, or doubtful. There was strong evidence of interaction in 39 of the 81 different drugs and foods appraised; 17 potentiate warfarin effect and 10 inhibit it, but 12 produce no effect. Many other drugs have been reported to either interact with oral anticoagulants or alter the PT response to warfarin

(69,70). A recent review highlighted the importance of postmarketing surveillance with newer drugs, such as celecoxib, a drug that showed no interactions in Phase 2 studies but was subsequently suspected of potentiating the effect of warfarin in several case reports (71). This review also drew attention to potential interactions with less well-regulated herbal medicines. For these reasons, the INR should be measured more frequently when virtually any drug or herbal medicine is added or withdrawn from the regimen of a patient treated with warfarin.

### The Antithrombotic Effect of Warfarin

The antithrombotic effect of warfarin conventionally has been attributed to its anticoagulant effect, which in turn is mediated by the reduction of 4 vitamin K-dependent coagulation factors. More recent evidence, however, suggests that the anticoagulant and antithrombotic effects can be dissociated and that reduction of prothrombin and possibly factor X are more important than reduction of factors VII and IX for the antithrombotic effect. This evidence is indirect and derived from the following observations: First, the experiments of Wessler and Gitel (72) more than 40 years ago, which used a stasis model of thrombosis in rabbits, showed

that the antithrombotic effect of warfarin requires 6 days of treatment, whereas an anticoagulant effect develops in 2. The antithrombotic effect of warfarin requires reduction of prothrombin (factor II), which has a relatively long half-life of ≈60 to 72 hours, compared with 6 to 24 hours for other K-dependent factors responsible for the more rapid anticoagulant effect. Second, in a rabbit model of tissue factor-induced intravascular coagulation, the protective effect of warfarin is mainly a result of lowering prothrombin levels (73). Third, Patel and associates (74) demonstrated that clots formed from umbilical cord plasma (containing about half the prothrombin concentration of adult control plasma) generated significantly less fibrinopeptide A, reflecting less thrombin activity, than clots formed from maternal plasma. The view that warfarin exerts its antithrombotic effect by reducing prothrombin levels is consistent with observations that clot-bound thrombin is an important mediator of clot growth (75) and that reduction in prothrombin levels decreases the amount of thrombin generated and bound to fibrin, reducing thrombogenicity (74).

The suggestion that the antithrombotic effect of warfarin is reflected in lower levels of prothrombin forms the basis for overlapping heparin with warfarin until the PT (INR) is prolonged into the therapeutic range during treatment of patients with thrombosis. Because the half-life of prothrombin is ≈60 to 72 hours, ≥4 days' overlap is necessary. Furthermore, the levels of native prothrombin antigen during warfarin therapy more closely reflect antithrombotic activity than the PT (76). These considerations support administering a maintenance dose of warfarin (≈5 mg daily) rather than a loading dose when initiating therapy. The rate of lowering prothrombin levels was similar with either a 5- or a 10-mg initial warfarin dose (77), but the anticoagulant protein C was reduced more rapidly and more patients were excessively anticoagulated (INR >3.0) with a 10-mg loading dose.

## Management of Oral Anticoagulant Therapy

### Monitoring Anticoagulation Intensity

The PT is the most common test used to monitor oral anticoagulant therapy (78). The PT responds to reduction of 3 of the 4 vitamin K-dependent procoagulant clotting factors (II, VII, and X) that are reduced by warfarin at a rate proportionate to their respective half-lives. Thus, during the first few days of warfarin therapy, the PT reflects mainly reduction of factor VII, the half-life of which is ≈6 hours. Subsequently, reduction of factors X and II contributes to prolongation of the PT. The PT assay is performed by adding calcium and thromboplastin to citrated plasma. The traditional term "thromboplastin" refers to a phospholipid-protein extract of tissue (usually lung, brain, or placenta) that contains both the tissue factor and phospholipid necessary to promote activation of factor X by factor VII. Thromboplastins vary in responsiveness to the anticoagulant effects of warfarin according to their source, phospholipid content, and preparation (79–81). The responsiveness of a given thromboplastin to warfarin-induced changes in clotting factors reflects the intensity of activation of factor X by the factor VIIa/tissue factor complex. An unresponsive thromboplastin

produces less prolongation of the PT for a given reduction in vitamin K-dependent clotting factors than a responsive one. The responsiveness of a thromboplastin can be measured by assessing its International Sensitivity Index (ISI) (see below).

PT monitoring of warfarin treatment is very imprecise when expressed as a PT ratio (calculated as a simple ratio of the patient's plasma value over that of normal control plasma) because thromboplastins can vary markedly in their responsiveness to warfarin. Differences in thromboplastin responsiveness contributed to clinically important differences in oral anticoagulant dosing among countries (82) and were responsible for excessive and erratic anticoagulation in North America, where less responsive as well as responsive thromboplastins were in common use. Recognition of these shortcomings in PT monitoring stimulated the development of the INR standard for monitoring oral anticoagulant therapy, and the adoption of this standard improved the safety of oral anticoagulant therapy and its ease of monitoring.

The history of standardization of the PT has been reviewed by Poller (80) and by Kirkwood (83). In 1992, the ISI of thromboplastins used in the United States varied between 1.4 and 2.8 (84). Subsequently, more responsive thromboplastins with lower ISI values have come into clinical use in the United States and Canada. For example, the recombinant human preparations consisting of relipidated synthetic tissue factor have ISI values of 0.9 to 1.0 (85). The INR calibration model, adopted in 1982, is now used to standardize reporting by converting the PT ratio measured with the local thromboplastin into an INR, calculated as follows:

$$\text{INR} = (\text{patient PT}/\text{mean normal PT})^{\text{ISI}}$$

or

$$\log \text{INR} = \text{ISI} (\log \text{observed PT ratio}),$$

where ISI denotes the International Sensitivity Index of the thromboplastin used at the local laboratory to perform the PT measurement. The ISI reflects the responsiveness of a given thromboplastin to reduction of the vitamin K-dependent coagulation factors. The more responsive the reagent, the lower the ISI value (80,83,86).

Most commercial manufacturers provide ISI values for thromboplastin reagents, and the INR standard has been widely adopted by hospitals in North America. Thromboplastins with recombinant tissue factor have been introduced with ISI values close to 1.0, yielding PT ratios virtually equivalent to the INR. According to the College of American Pathologists Comprehensive Coagulation Survey, implementation of the INR standard in the United States increased from 21% to 97% between 1991 and 1997 (82). As the INR standard of reporting was widely adopted, however, several problems surfaced. These are reviewed briefly below.

As noted above, the INR is based on ISI values derived from plasma of patients on stable anticoagulant doses for ≥6 weeks (87). As a result, the INR is less reliable early in the course of warfarin therapy, particularly when results are obtained from different laboratories. Even under these conditions, however, the INR is more reliable than the unconverted PT ratio (88) and is thus recommended during both initiation and maintenance of warfarin treatment. There is

also evidence that the INR is a reliable measure of impaired blood coagulation in patients with liver disease (89).

Theoretically, the INR could be made more precise by using reagents with low ISI values, but laboratory proficiency studies indicate that this produces only modest improvement (90–93), whereas reagents with higher ISI values result in higher coefficients of variation (94,95). Variability of ISI determination is reduced by calibrating the instrument with lyophilized plasma depleted of vitamin K-dependent clotting factors (95–97). Because the INR is based on a mathematical relationship using a manual method for clot detection, the accuracy of the INR measurement can be influenced by the automated clot detectors now used in most laboratories (98–103). In general, the College of American Pathologists has recommended that laboratories use responsive thromboplastin reagents (ISI <1.7) and reagent/instrument combinations for which the ISI has been established (104).

ISI values provided by manufacturers of thromboplastin reagents are not invariably correct (105–107), and this adversely affects the reliability of measurements. Local calibrations can be performed by using plasma samples with certified PT values to determine the instrument-specific ISI. The mean normal plasma PT is determined from fresh plasma samples from  $\geq 20$  healthy individuals and is not interchangeable with a laboratory control PT (108). Because the distribution of PT values is not normal, log-transformation and calculation of a geometric mean are recommended. The mean normal PT should be determined with each new batch of thromboplastin with the same instrument used to assay the PT (108).

The concentration of citrate used to anticoagulate plasma affects the INR (109,110). In general, higher citrate concentrations ( $\geq 3.8\%$ ) lead to higher INR values (109), and underfilling the blood collection tube spuriously prolongs the PT because excess citrate is present. Using collection tubes containing 3.2% citrate for blood coagulation studies can reduce this problem.

The lupus anticoagulants prolong the activated partial thromboplastin time but usually cause only slight prolongation of the PT, according to the reagents used (111,112). The prothrombin and proconvertin tests (113,114) and measurements of prothrombin activity or native prothrombin concentration have been proposed as alternatives (76,114–116), but the optimum method for monitoring anticoagulation in patients with lupus anticoagulants is uncertain.

### Practical Warfarin Dosing and Monitoring

Warfarin dosing may be separated into initial and maintenance phases. After treatment is started, the INR response is monitored frequently until a stable dose-response relationship is obtained; thereafter, the frequency of INR testing is reduced.

An anticoagulant effect is observed within 2 to 7 days after beginning oral warfarin, according to the dose administered. When a rapid effect is required, heparin should be given concurrently with warfarin for  $\geq 4$  days. The common practice of administering a loading dose of warfarin is generally unnecessary, and there are theoretical reasons for beginning treatment with the average maintenance dose of  $\approx 5$  mg daily,

which usually results in an INR of  $\geq 2.0$  after 4 or 5 days. Heparin usually can be stopped once the INR has been in the therapeutic range for 2 days. When anticoagulation is not urgent (eg, chronic atrial fibrillation), treatment can be commenced out of hospital with a dose of 4 to 5 mg/d, which usually produces a satisfactory anticoagulant effect within 6 days (77). Starting doses  $< 4$  to 5 mg/d should be used in patients sensitive to warfarin, including the elderly (40,117), and in those at increased risk of bleeding.

The INR is usually checked daily until the therapeutic range has been reached and sustained for 2 consecutive days, then 2 or 3 times weekly for 1 to 2 weeks, then less often, according to the stability of the results. Once the INR becomes stable, the frequency of testing can be reduced to intervals as long as 4 weeks. When dose adjustments are required, frequent monitoring is resumed. Some patients on long-term warfarin therapy experience unexpected fluctuations in dose-response due to changes in diet, concurrent medication changes, poor compliance, or alcohol consumption.

The safety and effectiveness of warfarin therapy depends critically on maintaining the INR within the therapeutic range. On-treatment analysis of the primary prevention trials in atrial fibrillation found that a disproportionate number of thromboembolic and bleeding events occurred when the PT ratio was outside the therapeutic range (118). Subgroup analyses of other cohort studies also have shown a sharp increase in the risk of bleeding when the INR is higher than the upper limit of the therapeutic range (116,119–122), and the risk of thromboembolism increased when the INR fell to  $< 2.0$  (123,124).

### Point-of-Care Patient Self-Testing

Point-of-care (POC) PT measurements offer the potential for simplifying oral anticoagulation management in both the physician's office and the patient's home. POC monitors measure a thromboplastin-mediated clotting time that is converted to plasma PT equivalent by a microprocessor and expressed as either the PT or the INR. The original methodology was incorporated into the Biotrack instrument (Coumatrak; Biotrack, Inc) evaluated by Lucas et al (125) in 1987. These investigators reported a correlation coefficient ( $r$ ) of 0.96 between reference plasma PT and capillary whole blood PT, findings that were confirmed in other studies (126).

By early 2000, the US Food and Drug Administration (FDA) had approved 3 monitors for patient self-testing at home (127), but each instrument has limitations. Instruments currently marketed for this purpose are listed in Table 1. In a study (128) in which a derivative of the Biotrack monitor (Biotrack 512; Ciba-Corning) was used, the POC instrument compared poorly with the Thrombotest, the former underestimating the INR by a mean of 0.76. Another Biotrack derivative (Coumatrak; DuPont) was accurate in an INR range of 2.0 to 3.0 but gave discrepant results at higher INR values (129). In another study, the Ciba-Corning monitor underestimated the results when the INR was  $> 4.0$ , but the error was overcome by using a revised ISI value to calculate the INR (130). Several investigators (131–133) reported

TABLE 2. Studies of Patient Self-Testing and Self-Management of Anticoagulation

Study	Study Design	Study Groups	No. of Patients	Time in Range, % INR % Time	Major Hemorrhage, % per patient-year	Thromboembolism, % per patient-year	Indications
White <sup>140</sup> 1989	RCT	PST	23	93	0	0	Mixed
		AMS	23	75	0	0	Mixed
Anderson <sup>139</sup> 1993	Inception cohort	PST	40	74	0	0	Mixed
		PST	162	56	5.7	9	Mixed
Beyth <sup>141</sup> 1997	RCT	PST	163	33	12	13	Mixed
		UC	163				
Ansell <sup>145</sup> 1995	Observational cohort	PSM	20	89	0	0	Mixed
		AMS	20	68	0	0	Mixed
Bernardo <sup>146</sup> 1996	Observational	PSM	216	83	NA	NA	Heart valves
Horstkotte <sup>147</sup> 1996	RCT	PSM	75	92	4.5*	0.9	Heart valves
		UC	75	59	10.9*	3.6	Heart valves
Hasenkam <sup>142</sup> 1997	Observational matched control	PSM	20	77	NA	NA	Heart valves
		UC	20	53	NA	NA	Heart valves
Sawicki <sup>148</sup> 1999	RCT	PSM	90	57/53†	2.2	2.2	Mixed
		UC	89	34/43†	2.2	4.5	Mixed
Kortke <sup>149</sup> 2001	RCT	PSM	305	78	1.7	1.2	Mixed
		UC	295	60	2.6	2.1	Mixed
Watzke <sup>150</sup> 2000	Prospective controlled	PSM	49	86	4‡	0	Mixed
		ACC	53	80	0	0	Mixed
Cromheecke <sup>151</sup> 2000	Randomized crossover	PSM	50	55	0	0	Mixed
		ACC	50	49	0	16	Mixed

RCT indicates randomized controlled trial; PST, patient self-testing; PSM, patient self-management; AMS, anticoagulation management service; UC, usual care; and Mixed, mixed indications.

\*Major and minor bleeding.

†Time in target range at 3 and 6 mo.

‡Percentage of episodes in 49 patients.

excellent correlations with reference plasma PT values when a second category of monitor (CoaguChek; Roche Diagnostics, Inc) was used. The ISI calibration with this system, based on an international reference preparation, was ex-

tremely close to indices adopted by the manufacturer for both whole blood and plasma (134). Both classes of monitors (Biotrack and Coagu-Chek) compared favorably with traditionally obtained PT measurements at 4 laboratories and with

TABLE 3. Relationship Between Anticoagulation Intensity and Bleeding

Source	No. of Patients	Duration of Therapy	Target INR Range	Incidence of Bleeding, %	P
Hull et al 1982 <sup>167</sup> —deep vein thrombosis	96	3 mo	3.0–4.5 vs 2.0–2.5	22.4 vs 4.3	0.015
Turpie et al 1988 <sup>168</sup> —prosthetic heart valves (tissue)	210	3 mo	2.5–4.0 vs 2.0–2.5	13.9 vs 5.9	<0.002
Saour et al 1990 <sup>169</sup> —mechanical prosthetic heart valves	247	3.47 y	7.4–10.8 vs 1.9–3.6	42.4 vs 21.3	<0.002
Altman et al 1991 <sup>170</sup> —mechanical prosthetic heart valves*	99	11.2 mo	3.0–4.5 vs 2.0–2.9	24.0 vs 6.0	<0.02

\*Patients also given aspirin 300 mg daily, and dipyridamole 75 mg BID.

the standard manual tilt-tube technique established by the World Health Organization using an international reference thromboplastin (135). Laboratories using a more sensitive thromboplastin showed close agreement with the standard, whereas agreement was poor when insensitive thromboplastins were used; INR determinations with the Coumatrak and CoaguChek monitors were only slightly less accurate than the conventional method used in the best clinical laboratories.

A third category of POC capillary whole blood PT instruments (ProTIME Monitor; International Technidyne Corporation) differs from the other 2 types of instruments in that it performs a PT in triplicate (3 capillary channels) and simultaneously performs level 1 and level 2 controls (2 additional capillary channels). In a multiinstitutional trial (136), the instrument INR correlated well with reference laboratory tests and those performed by a healthcare provider (venous sample,  $r=0.93$ ; capillary sample,  $r=0.93$ ; patient fingerstick,  $r=0.91$ ). In a separate report involving 76 warfarin-treated children and 9 healthy control subjects, the coefficient of correlation between venous and capillary samples was 0.89. Compared with venous blood tested in a reference laboratory (ISI=1.0), correlation coefficients were 0.90 and 0.92, respectively (137). Published results with a fourth type of PT monitor (Avocet PT 1000) in 160 subjects demonstrate good correlation when compared with reference laboratory INR values with capillary blood, citrated venous whole blood, and citrated venous plasma ( $r=0.97$ , 0.97, and 0.96, respectively) (138).

The feasibility and accuracy of patient self-testing at home initially was evaluated in 2 small studies with promising results (139,140). More recently, Beyth and Landefeld (141) randomized 325 newly treated elderly patients to either conventional treatment by personal physicians based on venous sampling or adjustment of dosage by a central investigator based on INR results from patient self-testing at home. Over a 6-month period, the rate of hemorrhage was 12% in the usual-care group compared with 5.7% in the self-testing group. These and other studies in which patient self-testing and self-management of anticoagulation have been evaluated are summarized in Table 2 (142).

### Patient Self-Management

Coupled with self-testing, self-management with the use of POC instruments offers independence and freedom of travel to selected patients. The feasibility of initial patient self-management of oral anticoagulation was demonstrated in several studies (143-146). These descriptive studies were then followed by several randomized trials. In the first study, 75 patients with prosthetic heart valves who managed their own therapy were compared with a control group of the same size managed by their personal physicians (147). The self-managed patients tested themselves approximately every 4 days and achieved a 92% degree of satisfactory anticoagulation, as determined by the INR. The physician-managed patients were tested approximately every 19 days, but only 59% of INR values were in therapeutic range. Self-managed individuals experienced a 4.5% per year incidence of bleeding of any severity and a 0.9% per year rate of thromboembolism, compared with 10.9% and 3.6%, respectively, in the

physician-managed group ( $P<0.05$  between groups). Another comparison of self-management ( $n=90$ ) with usual care ( $n=89$ ) (148) found that the difference in the percentage of INR values within the therapeutic range at 3 months became statistically insignificant at 6 months. Results from the large, randomized Early Self-Controlled Anticoagulation Study in Germany (ESCAT) (149) showed that among 305 self-managed patients, INR values were more frequently in range (78%) compared with 61% in 295 patients assigned to usual care. The rate of major adverse events was significantly different between groups: 2.9% per patient-year of therapy in the self-managed group versus 4.7% in the usual-care group ( $P=0.042$ ).

When patient self-management is compared with the outcomes of high-quality anticoagulation management delivered by an anticoagulation clinic, the differences between the 2 methods of management are less marked. Watzke et al (150) compared weekly INR patient self-management in 49 patients with management by an anticoagulation clinic in 53 patients. There was no significant difference for time in therapeutic range between groups, but the self-management group had a significantly smaller mean deviation from their target INR. Cromheecke et al (151) conducted a randomized crossover study with 50 patients managed by an anticoagulation clinic or by self-management. Although the differences did not achieve statistical significance, there was a trend toward greater time in therapeutic range in the self-management group (55% versus 49%).

Preliminary results from 2 recent studies further suggest that when compared with anticoagulation clinic management, patient self-testing or patient self-management offers limited advantages. Both Gadisseur et al (152) and Kaatz et al (153) found that time in therapeutic range was the same regardless of whether patients self-tested and self-managed or were managed by an anticoagulation clinic.

### Computerized Algorithms for Warfarin Dose Adjustment

Several computer programs have been developed to guide warfarin dosing. They are based on various techniques: querying physicians (154), Bayesian forecasting (155), and a proprietary mathematical equation (156). In general, the latter involve fixed-effects log-linear Bayesian modeling, which accounts for factors unique to each measurement. The response variance not explained by previous warfarin dose and previous INR values is specific and constant over time for each patient but not entirely accounted for mathematically. In one randomized trial, the reliability of 3 established computerized dosage programs were compared with warfarin dosing by experienced medical staff in an outpatient clinic (157). Control was similar with the computer-guided and empirical dose adjustments in the INR range of 2.0 to 3.0, but the computer programs achieved significantly better control when more intensive therapy (INR 3.0 to 4.5) was required. In another randomized study of 101 chronically anticoagulated patients with prosthetic cardiac valves, computerized warfarin adjustments proved comparable to manual regulation in the percentage of INR values kept within the therapeutic range but required 50% fewer dose adjustments (158).

A multicenter randomized study of 285 patients found computer-assisted dose regulation more effective than traditional dosing at maintaining therapeutic INR values. Taken together, these data suggest that computer-guided warfarin dose adjustment is superior to traditional dose regulation, particularly when personnel are inexperienced.

### Management of Patients With High INR Values

There is a close relation between the INR and risk of bleeding (Table 1). The risk of bleeding increases when the INR exceeds 4, and the risk rises sharply with values  $>5$ . Three approaches can be taken to lower an elevated INR. The first step is to stop warfarin; the second is to administer vitamin K<sub>1</sub>; and the third and most rapidly effective measure is to infuse fresh plasma or prothrombin concentrate. The choice of approach is based largely on clinical judgment because no randomized trials have compared these strategies with clinical end points. After warfarin is interrupted, the INR falls over several days (an INR between 2.0 and 3.0 falls to the normal range 4 to 5 days after warfarin is stopped) (159). In contrast, the INR declines substantially within 24 hours after treatment with vitamin K<sub>1</sub> (160).

Even when the INR is excessively prolonged, the absolute daily risk of bleeding is low, leading many physicians to manage patients with INR levels as high as 5 to 10 by stopping warfarin expectantly, unless the patient is at intrinsically high risk of bleeding or bleeding has already developed. Ideally, vitamin K<sub>1</sub> should be administered in a dose that will quickly lower the INR into a safe but not subtherapeutic range without causing resistance once warfarin is reinstated or exposing the patient to the risk of anaphylaxis. Though effective, high doses of vitamin K<sub>1</sub> (eg, 10 mg) may lower the INR more than necessary and lead to warfarin resistance for up to a week. Vitamin K<sub>1</sub> can be administered intravenously, subcutaneously, or orally. Intravenous injection produces a rapid response but may be associated with anaphylactic reactions, and there is no proof that this rare but serious complication can be avoided by using low doses. The response to subcutaneous vitamin K<sub>1</sub> is unpredictable and sometimes delayed (161,162). In contrast, oral administration is predictably effective and has the advantages of convenience and safety over parenteral routes. In patients with excessively prolonged INR values, vitamin K<sub>1</sub>, 1 mg to 2.5 mg orally, more rapidly lowers the INR to  $<5$  within 24 hours than simply withholding warfarin (163). In a prospective study of 62 warfarin-treated patients with INR values between 4 and 10, warfarin was omitted, and vitamin K<sub>1</sub>, 1 mg, was administered orally (162,164). After 24 hours, the INR was lower in 95%,  $<4$  in 85%, and  $<1.9$  in 35%. None displayed resistance when warfarin was resumed. These observations indicate that oral vitamin K<sub>1</sub> in low doses effectively reduces the INR in patients treated with warfarin. Oral vitamin K<sub>1</sub>, 1.0 to 2.5 mg, is sufficient when the INR is between 4 and 10, but larger doses (5 mg) are required when the INR is  $>10$ .

Oral vitamin K<sub>1</sub> is the treatment of choice unless very rapid reversal of anticoagulation is critical, when vitamin K<sub>1</sub> can be administered by slow intravenous infusion (5 to 10 mg over 30 minutes). In 2001, the American College of Chest Physi-

cians published the following recommendations for managing patients on coumarin anticoagulants who need their INRs lowered because of either actual or potential bleeding (164):

- (1) When the INR is above the therapeutic range but  $<5$ , the patient has not developed clinically significant bleeding, and rapid reversal is not required for surgical intervention, the dose of warfarin can be reduced or the next dose omitted and resumed (at a lower dose) when the INR approaches the desired range.
- (2) If the INR is between 5 and 9 and the patient is not bleeding and has no risk factors that predispose to bleeding, the next 1 or 2 doses of warfarin can be omitted and warfarin reinstated at a lower dose when the INR falls into the therapeutic range. Alternatively, the next dose of warfarin may be omitted and vitamin K<sub>1</sub> (1 to 2.5 mg) given orally. This approach should be used if the patient is at increased risk of bleeding.
- (3) When more rapid reversal is required to allow urgent surgery or dental extraction, vitamin K<sub>1</sub> can be given orally in a dose of 2 to 5 mg, anticipating reduction of the INR within 24 hours. An additional dose of 1 or 2 mg vitamin K can be given if the INR remains high after 24 hours.
- (4) If the INR is  $>9$  but clinically significant bleeding has not occurred, vitamin K<sub>1</sub>, 3 to 5 mg, should be given orally, anticipating that the INR will fall within 24 to 48 hours. The INR should be monitored closely and vitamin K repeated as necessary.
- (5) When rapid reversal of anticoagulation is required because of serious bleeding or major warfarin overdose (eg, INR  $>20$ ), vitamin K<sub>1</sub> should be given by slow intravenous infusion in a dose of 10 mg, supplemented with transfusion of fresh plasma or prothrombin complex concentrate, according to the urgency of the situation. It may be necessary to give additional doses of vitamin K<sub>1</sub> every 12 hours.
- (6) In cases of life-threatening bleeding or serious warfarin overdose, prothrombin complex concentrate replacement therapy is indicated, supplemented with 10 mg of vitamin K<sub>1</sub> by slow intravenous infusion; this can be repeated, according to the INR. If warfarin is to be resumed after administration of high doses of vitamin K, then heparin can be given until the effects of vitamin K have been reversed and the patient again becomes responsive to warfarin.

### Bleeding During Oral Anticoagulant Therapy

The main complication of oral anticoagulant therapy is bleeding, and risk is related to the intensity of anticoagulation (Table 3) (165-170). Other contributing factors are the underlying clinical disorder (165,171) and concomitant administration of aspirin, nonsteroidal antiinflammatory drugs, or other drugs that impair platelet function, produce gastric erosions, and in very high doses impair synthesis of vitamin K-dependent clotting factors (57,60,62). The risk of major bleeding also is related to age  $>65$  years, a history of stroke or gastrointestinal bleeding, and comorbid conditions such as renal insufficiency or anemia (164,165). These risk factors are additive; patients with 2 or 3 risk factors have a much higher incidence of warfarin-associated bleeding than those with none or one (172). The elderly are more prone to bleeding even after controlling for anticoagulation intensity

(118,167). Bleeding that occurs at an INR of  $<3.0$  is frequently associated with trauma or an underlying lesion in the gastrointestinal or urinary tract (165).

Four randomized studies have demonstrated that lowering the INR target range from 3.0 to 4.5 to 2.0 to 3.0 reduces the risk of clinically significant bleeding (167–169). Although this difference in anticoagulant intensity is associated with an average warfarin dose reduction of only  $\approx 1$  mg/d, the effect on bleeding risk is impressive. It is prudent to initiate warfarin at lower doses in the elderly, as patients  $>75$  years of age require  $\approx 1$  mg/d less than younger individuals to maintain comparable prolongation of the INR.

Long-term management is challenging for patients who have experienced bleeding during warfarin anticoagulation yet require thromboembolic prophylaxis (eg, those with mechanical heart valves or high-risk patients with atrial fibrillation). If bleeding occurred when the INR was above the therapeutic range, warfarin can be resumed once bleeding has stopped and its cause corrected. For patients with mechanical prosthetic heart valves and persistent risk of bleeding during anticoagulation in the therapeutic range, a target INR of 2.0 to 2.5 seems sensible. For those in this situation with atrial fibrillation, anticoagulant intensity can be reduced to an INR of 1.5 to 2.0, anticipating that efficacy will be diminished but not abolished (123). In certain subgroups of patients with atrial fibrillation, aspirin may be an appropriate alternative to warfarin (173).

### Management of Anticoagulated Patients Who Require Surgery

The management of patients treated with warfarin who require interruption of anticoagulation for surgery or other invasive procedures can be problematic. Several approaches can be taken, according to the risk of thromboembolism (174). In most patients, warfarin is stopped 4 to 5 days preoperatively, thereby allowing the INR to return to normal ( $<1.2$ ) at the time of the procedure. Such patients remain unprotected for  $\approx 2$  to 3 days preoperatively. The period off warfarin can be reduced to 2 days by giving vitamin K<sub>1</sub>, 2.5 mg orally, 2 days before the procedure with the expectation that the patient will remain unprotected for  $<2$  days and that the INR will return to normal at the time of the procedure. Heparin can be given preoperatively to limit the period of time that the patient remains unprotected, and anticoagulant therapy can be recommenced postoperatively once it is deemed to be safe to restart treatment. Low-molecular-weight heparin (LMWH) can be used instead of heparin, but information on its efficacy in patients with prosthetic heart valves who require intercurrent surgery is lacking.

Moreover, the FDA and Aventis strengthened the “Warning” and “Precautions” sections of the Lovenox prescribing information to inform health professionals that the use of Lovenox injection is not recommended for thromboprophylaxis in patients with prosthetic heart valves.

- For patients at moderate risk of thromboembolism, preoperative heparin in prophylactic doses of 5000 U (or LMWH in prophylactic doses of 3000 U) can be given subcutaneously every 12 hours. Heparin (or LMWH) in these

prophylactic doses can be restarted 12 hours postoperatively along with warfarin and the combination continued for 4 to 5 days until the INR returns to the desired range. If patients are considered to be at high risk of postoperative bleeding, heparin or LMWH can be delayed for 24 hours or longer.

- For patients at high risk of thromboembolism, low doses of heparin or LMWH might not provide adequate protection after warfarin is discontinued preoperatively, and these high-risk patients should be treated with therapeutic doses of heparin (15 000 U every 12 hours by subcutaneous injection) or LMWH (100 U/kg every 12 hours by subcutaneous injection). These anticoagulants can be administered on an ambulatory basis or in hospital and discontinued 24 hours before surgery with the expectation that their effect will last until 12 hours before surgery. If maintaining preoperative anticoagulation is considered to be critical, the patient can be admitted to hospital, and heparin can be administered in full doses (1300 U/h) by continuous intravenous infusion and stopped 5 hours before surgery, allowing the activated partial thromboplastin time to return to baseline at the time of the procedure. Heparin or LMWH can then be restarted in prophylactic doses 12 hours postoperatively along with warfarin and continued until the INR reaches the desired range.
- For patients at low risk of thromboembolism (eg, atrial fibrillation), the dose of warfarin can be reduced 4 to 5 days in advance of surgery to allow the INR to fall to normal or near normal (1.3 to 1.5) at the time of surgery. The maintenance dose of warfarin is resumed postoperatively and supplemented with low-dose heparin (5000 U) or LMWH administered subcutaneously every 12 hours, if necessary.
- Finally, for patients undergoing dental procedures, tranexamic acid or  $\epsilon$ -aminocaproic acid mouthwash can be applied without interrupting anticoagulant therapy (175,176).

### Anticoagulation During Pregnancy

Oral anticoagulants cross the placenta and can produce a characteristic embryopathy with first-trimester exposure and, less commonly, central nervous system abnormalities and fetal bleeding with exposure after the first trimester (17). For this reason, it has been recommended that warfarin therapy be avoided during the first trimester of pregnancy and, except in special circumstances, avoided entirely throughout pregnancy. Because heparin does not cross the placenta, it is the preferred anticoagulant in pregnant women. Several reports of heparin failure resulting in serious maternal consequences involving patients with mechanical heart valves, however (170,177,178), have caused some authorities to recommend that warfarin be used preferentially in women with mechanical prosthetic valves during the second and third trimesters of pregnancy. It even has been suggested that the inadequacy of heparin for prevention of maternal thromboembolism might outweigh the risk of warfarin embryopathy during the first trimester. Although reports of heparin failures in pregnant women with mechanical prosthetic valves could reflect inadequate dosing, it also is possible that heparin is a less

effective antithrombotic agent than warfarin in patients with prosthetic heart valves. This notion is supported by recent experience with LMWH in pregnant women with prosthetic heart valves. Thus, as described above (see Management of Anticoagulated Patients Who Require Surgery), the FDA and Aventis have issued an advisory warning against the use of Lovenox in pregnant women with mechanical prosthetic heart valves. This warning was based on a randomized trial comparing enoxaparin to warfarin in pregnant patients with prosthetic heart valves. In contrast to the reported problems of using heparin or LMWH in pregnant patients with mechanical prosthetic valves, Montalescot and associates (179) reported that LMWH produced safe and effective anticoagulation when given for an average of 14.1 days to 102 nonpregnant patients with mechanical prosthetic heart valves. Nevertheless, it should be emphasized that LMWH is not approved by the FDA for use in any patients with mechanical prosthetic heart valves.

Given the potential medico-legal implications in the United States of using warfarin during pregnancy, the FDA warning related to the use of Lovenox, and the reported lack of efficacy of heparin in pregnant patients with mechanical prosthetic valves, physicians managing these patients are faced with a real dilemma. Three options are available. These are to use: (1) heparin or LMWH throughout pregnancy; (2) warfarin throughout pregnancy, changing to heparin or LMWH at 38 weeks' gestation with planned labor induction at  $\approx 40$  weeks; or (3) heparin or LMWH in the first trimester of pregnancy, switching to warfarin in the second trimester, continuing it until  $\approx 38$  weeks' gestation, and then changing to heparin or LMWH at 38 weeks with planned labor induction at  $\approx 40$  weeks. If heparin or LMWH is used in pregnant women with mechanical prosthetic valves, they should be administered in adequate doses and monitored carefully. Heparin should be given subcutaneously twice daily, starting at a total daily dose of 35 000 U. Monitoring should be performed at least twice weekly with either activated partial thromboplastin time or heparin assays, and higher heparin requirements should be anticipated in the third trimester because of an increase in heparin-binding proteins. LMWH should be given subcutaneously in a dose of 100 anti-Xa U/kg twice daily and the dose adjusted to maintain the anti-Xa level between 0.5 and 1.0 U/mL 4 to 6 hours after injection. Heparin or LMWH should be discontinued 12 hours before planned induction of labor. Heparin or LMWH should be started postpartum and overlapped with warfarin for 4 to 5 days. There is convincing evidence that, when administered to a nursing mother, warfarin does not induce an anticoagulant effect in the breast-fed infant (180,181).

### Nonhemorrhagic Adverse Effects of Warfarin

Other than hemorrhage, the most important side effect of warfarin is skin necrosis. This uncommon complication usually is observed on the third to eighth day of therapy (182,183) and is caused by extensive thrombosis of venules and capillaries within subcutaneous fat. The pathogenesis of this striking complication is uncertain. An association between warfarin-induced skin necrosis and protein C deficiency (184–186) and, less commonly, protein S deficiency

(187) has been reported, but warfarin-induced skin necrosis also occurs in patients without these deficiencies. A pathogenic role for protein C deficiency is supported by the similarity of the necrotic lesions to those of neonatal purpura fulminans, which complicates homozygous protein C deficiency. Patients with coumarin-induced skin necrosis who require further anticoagulant therapy are problematic. Warfarin is considered contraindicated, and long-term treatment with heparin is inconvenient and associated with osteoporosis. A reasonable approach is to restart warfarin at a low dose (eg, 2 mg daily), while therapeutic doses of heparin are administered concurrently, and gradually increase warfarin over several weeks. This approach should avoid an abrupt fall in protein C levels before reduction in levels of factors II, IX, and X occurs, and several case reports have suggested that warfarin can be resumed in this way without recurrence of skin necrosis (184,185).

### Clinical Applications of Oral Anticoagulant Therapy

The clinical effectiveness of oral anticoagulants has been established by well-designed clinical trials in a variety of disease conditions. Oral anticoagulants are effective for primary and secondary prevention of venous thromboembolism, for prevention of systemic embolism in patients with prosthetic heart valves or atrial fibrillation, for prevention of acute myocardial infarction (AMI) in patients with peripheral arterial disease and in men otherwise at high risk, and for prevention of stroke, recurrent infarction, or death in patients with AMI (64). Although effectiveness has not been proved by a randomized trial, oral anticoagulants also are indicated for prevention of systemic embolism in high-risk patients with mitral stenosis and in patients with presumed systemic embolism, either cryptogenic or in association with a patent foramen ovale. For most of these indications, a moderate anticoagulant intensity (INR 2.0 to 3.0) is appropriate.

Although anticoagulants are sometimes used for secondary prevention of cerebral ischemia of presumed arterial origin when antiplatelet agents have failed, the Stroke Prevention in Reversible Ischemia Trial (SPIRIT) study found high-intensity oral anticoagulation (INR 3.0 to 4.5) dangerous in such cases (121). The trial was stopped at the first interim analysis of 1316 patients with a mean follow-up of 14 months because there were 53 major bleeding complications during anticoagulant therapy (27 intracranial, 17 fatal) versus 6 on aspirin (3 intracranial, 1 fatal). The authors concluded that oral anticoagulants are not safe when adjusted to a targeted INR range of 3.0 to 4.5 in patients who have experienced cerebral ischemia of presumed arterial origin. In a second study (the Warfarin Aspirin Recurrent Stroke Study [WARSS]) (187a), 2206 patients with noncardioembolic ischemic stroke were randomly assigned to receive either low-intensity warfarin (INR 1.4 to 2.8) or aspirin (325 mg/d). The primary end point of death or recurrent ischemic stroke occurred 17.8 patients assigned to warfarin and 16.0 assigned to aspirin ( $P=0.25$ ). The rates of major bleeding were 2.2% and 1.5% in the warfarin and aspirin groups, respectively (not significant). Thus, low-intensity warfarin and aspirin exhibit

similar efficacy and safety in patients with noncardioembolic ischemic stroke.

### Prevention of Venous Thromboembolism

Oral anticoagulants when given at a dose sufficient to maintain an INR between 2.0 and 3.0 are effective for prevention of venous thrombosis after hip surgery (188–190) and major gynecologic surgery (191,192). The risk of clinically important bleeding at this intensity is modest. A very low fixed dose of warfarin (1 mg daily) prevented subclavian vein thrombosis in patients with malignancy who had indwelling catheters (193). In contrast, 4 randomized trials found this dose of warfarin ineffective for preventing post-operative venous thrombosis in patients undergoing major orthopedic surgery (194–197). Levine and associates (198) reported that warfarin, 1 mg daily for 6 weeks followed by adjustment to a targeted INR of 1.5, prevented thrombosis in patients with stage 4 breast cancer receiving chemotherapy. In general, when warfarin is used to prevent venous thromboembolism, the targeted INR should be 2.0 to 3.0.

### Treatment of Deep Venous Thrombosis or Pulmonary Embolism

The optimum duration of oral anticoagulant therapy is influenced by the competing risks of bleeding and recurrent venous thromboembolism. The risk of major bleeding during oral anticoagulant therapy is ≈3% per year with an annual case fatality rate of ≈0.6%. On the other hand, the case fatality rate from recurrent venous thromboembolism is ≈5% to 7%, with the rate being higher in patients with pulmonary embolism. Therefore, at an annual recurrence rate of 12%, the risk of death from recurrent thromboembolism is balanced by the risk of death from anticoagulant-related bleeding. The risk of recurrent thromboembolism when anticoagulant therapy is discontinued depends on whether thrombosis is unprovoked (idiopathic) or is secondary to a reversible cause; a longer course of therapy is warranted when thrombosis is idiopathic or associated with a continuing risk factor (199). The reported risk of recurrence in patients with idiopathic proximal vein thrombosis has been reported to be between 10% and 27% when anticoagulants are discontinued after 3 months. Extending therapy beyond 6 months seems to reduce the risk of recurrence to 7% during the year after treatment is discontinued (200).

Patients should be treated with anticoagulants for a minimum of 3 months. Moderate-intensity anticoagulation (INR 2.0 to 3.0) is as effective as a more intense regimen (INR 3.0 to 4.5) but is associated with less bleeding (166). Treatment should be longer in patients with proximal vein thrombosis than in those with distal thrombosis and in patients with recurrent thrombosis versus those with an isolated episode. Laboratory evidence of thrombophilia also may warrant a longer duration of anticoagulant therapy, according to the nature of the defect. Oral anticoagulant therapy is indicated for ≥3 months in patients with proximal deep vein thrombosis (201,202), for ≥6 months in those with proximal vein thrombosis in whom a reversible cause cannot be identified and eliminated or in patients with recurrent venous thrombosis, and for 6 to 12 weeks in patients with symptomatic calf

vein thrombosis (203–205). Indefinite anticoagulant therapy should be considered in patients with >1 episode of idiopathic proximal vein thrombosis, thrombosis complicating malignancy, or idiopathic venous thrombosis and homozygous factor V Leiden genotype, the antiphospholipid antibody syndrome, or deficiencies of antithrombin III, protein C, or protein S (206–208). Prospective cohort studies indicate that heterozygous factor V Leiden or the G20210A prothrombin gene mutation in patients with idiopathic venous thrombosis does not increase the risk of recurrence (207,209).

These recommendations are based on results of randomized trials (207) that demonstrated that oral anticoagulants effectively prevent recurrent venous thrombosis (risk reduction >90%), that treatment for 6 months is more effective than treatment for 6 weeks (206), and that treatment for 2 years is more effective than treatment for 3 months (208).

### Primary Prevention of Ischemic Coronary Events

The Thrombosis Prevention Trial (64) evaluated warfarin (target INR 1.3 to 1.8), aspirin (75 mg/d), both, or neither in 5499 men aged 45 to 69 years at risk of a first myocardial infarction (MI). The primary outcome was acute myocardial ischemia, defined as coronary death or nonfatal MI. Although the anticoagulant intensity was low, the mean warfarin dose was 4.1 mg/d. The annual incidence of coronary events was 1.4% per year in the placebo group, whereas the combination of warfarin and aspirin reduced the relative risk by 34% ( $P=0.006$ ). Given separately, neither warfarin nor aspirin produced a significant reduction in acute ischemic events, and the efficacy of the 2 drugs was similar (relative risk reductions 22% and 23% with warfarin and aspirin, respectively). The combined treatment, though most effective, was associated with a small but significant increase in hemorrhagic stroke. These results suggest that, in the primary prevention setting, low-intensity warfarin anticoagulation targeting an INR of 1.3 to 1.8 is effective for prevention of acute ischemic events (particularly fatal events) and that the combination of low-intensity warfarin plus aspirin is more effective than either agent alone, at the price of a small increase in bleeding.

Despite its effectiveness, low-intensity warfarin is not preferred over aspirin for primary prophylaxis in high-risk patients because warfarin requires INR monitoring and is associated with greater potential for bleeding.

The effectiveness of the combination of low-intensity warfarin plus aspirin in the Thrombosis Prevention Trial (64) contrasts with the results of the Coumadin Aspirin Reinfarction Study (CARS) (210), Stroke Prevention in Atrial Fibrillation (SPAF) III trial (124), and Post Coronary Artery Bypass Graft (Post-CABG) (211) study, in which this type of combination therapy was ineffective. In the Thrombosis Prevention Trial, the dose of warfarin was adjusted between 0.5 and 12.5 mg/d (INR of 1.3 to 1.8), whereas in the CARS and SPAF III studies, warfarin was given in fixed doses. The reason for the contrasting effectiveness of low-intensity warfarin in these primary and secondary prevention situations is not clear.

### Acute Myocardial Infarction

Initial evidence supporting use of oral anticoagulants in patients with AMI dates to the 1960s and 1970s, when

**TABLE 4. Randomized Trials in MI Comparing ASA, the Combination of ASA and Moderate- or Low-Intensity Warfarin, and High-Dose Warfarin: Efficacy**

Study (No. of patients; follow-up period)	Acute Coronary Syndromes Patients	Efficacy Outcome	ASA Efficacy Outcome, % (Dose)	OA [INR] Plus ASA Efficacy Outcome, % (Dose)	OA [INR]
ASPECT II <sup>119</sup> (n=993; 26 mo)	MI	Death, MI, stroke	9.0% (80 mg)	5.0% [2.0-2.5] (80 mg)	5.0% [3.0-4.0]
WARIS II <sup>222</sup> (n=3630; 48 mo)	MI	Death, MI, stroke	20% (160 mg)	16.7% [2.0-2.5] (75 mg)	15.0% [2.8-4.2]
APRICOT 2 <sup>221</sup> (n=308; 3 mo)	MI (All received thrombolytic therapy)	Reocclusion at 3 mo	30% (80 mg,160 mg)	18% [2.0-3.0] (80 mg,160 mg)	...
CARS <sup>210</sup> (n=8803; 14 mo)	MI	Death, MI, stroke	8.6% (160 mg)	8.4% [warfarin 3 mg] (80 mg)	...
CHAMP <sup>223</sup> (n=5059; 31 mo)	MI	Death, MI, stroke	33.9% (162 mg)	34% [1.5-2.5] (81 mg)	...

OA indicates oral anticoagulation.

warfarin given in moderate intensity (estimated INR of 1.5 to 2.5) was found effective for prevention of stroke and pulmonary embolism (212-216). Of 3 randomized trials in which the effectiveness of oral anticoagulants was evaluated in patients with AMI (213-215), 2 (213,215) showed a significant reduction in stroke but no significant impact on mortality, whereas there was a reduction in mortality in the third (214). In all 3 studies, the incidence of clinically diagnosed pulmonary embolism was reduced. Effectiveness of oral anticoagulants in the long-term management of patients with AMI was supported by the results of a meta-analysis of data pooled from 7 randomized trials published between 1964 and 1980, which showed that oral anticoagulants reduced the combined end points of mortality and nonfatal reinfarction by ≈20% during treatment periods of between 1 and 6 years (215-217).

Subsequently, a higher INR was evaluated in several European studies. The Sixty-Plus Re-infarction Study included patients >60 years of age who had been treated with oral anticoagulants for ≥6 months; lower rates of reinfarction and stroke were observed in patients randomized to continue anticoagulant therapy than in those from whom anticoagulation was withdrawn (218). As a treatment-interruption trial in a select age group, the findings were of limited generalizability. In another study with no age restriction (the WARfarin Re-Infarction Study [WARIS]), Smith and associates (219) reported a 50% reduction in the combined outcomes of recurrent infarction, stroke, and mortality. Similarly, the Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) trial (119), which also had no age restriction, reported ≥50% reduction in reinfarction and a 40% reduction in stroke among survivors of MI. Each of these studies (119,218,219) used high-intensity warfarin

regimens (INR 2.7 to 4.5 in the Sixty-Plus Study and 2.8 to 4.8 in the WARIS and ASPECT studies); each found the incidence of bleeding was increased with anticoagulants.

More recently, several studies have evaluated different intensities of anticoagulation, either alone or in combination with aspirin (Tables 4 and 5). The ASPECT II study compared warfarin alone (goal INR 3.0 to 4.0) with aspirin (80 mg daily) and with the combination of aspirin (80 mg daily) plus warfarin (INR 2.0 to 2.5) in 993 patients after an acute coronary syndrome. The sponsor halted the study because of slow recruitment when the composite end point of death, MI, and stroke occurred in 9.0% of patients on aspirin alone, 5.0% of those on warfarin alone, and 5.0% of those on the combined regimen. There was an excess of minor bleeding in those on the combination of warfarin (INR 2.0 to 2.5) and aspirin (220). In the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT) II study (221) of 308 patients with TIMI grade 3 coronary flow after thrombolysis for ST segment-elevation MI, aspirin (160 mg initially followed by 80 mg daily) was compared with aspirin in the same dosage combined with warfarin (INR 2.0 to 3.0) to assess the 3-month rate of angiographic reocclusion. Reocclusion occurred in 30% of the group given aspirin alone compared with 18% in those given aspirin plus warfarin (relative risk 0.60; 95% CI 0.39 to 0.93). There was an increase in minor but not major bleeding in the combination group (221). The WARIS II trial (222) compared warfarin or aspirin or both in 3630 patients <75 years of age with AMI randomized at the time of hospital discharge and followed up for 2 years for the first occurrence of the composite of all-cause death, nonfatal reinfarction, or thromboembolic stroke. This composite end point occurred in 20% of the patients on aspirin alone (160 mg/d), 16.7% of those on

**TABLE 5. Randomized Trials in MI Comparing ASA, the Combination of ASA and Moderate- or Low-Intensity Warfarin, and High-Dose Warfarin: Bleeding**

Study (No. of patients; follow-up period)	Acute Coronary Syndromes Patients	Bleeding	ASA	OA Plus ASA	OA (High Intensity)
ASPECT II <sup>119</sup> (n=993; 26 mo)	MI	Major	0.9%	2.1%	0.9%
WARIS II <sup>222</sup> (n=3630; 48 mo)	MI	Major	0.15% per y	0.58% per y	0.52% per y
APRICOT 2 <sup>221</sup> (n=308; 3 mo)	MI All received thrombolytic therapy	Total	3%	5%	
CARS <sup>210</sup> (n=8803; 14 mo)	MI	Spontaneous	0.74%	1.4%	

OA indicates oral anticoagulation.

**TABLE 6. Risk-Benefit Assessment of Oral Anticoagulant Therapy in Patients With Coronary Artery Disease: Meta-Analysis of 44 Trials Involving 24 115 Patients\***

Anticoagulation Intensity	No. of Trials (No. of Patients)	Ischemic Events Odds Ratio (95% CI)	P	Major Bleeding Odds Ratio	P
High vs control	16 (n=10 056)	0.57 (0.51–0.63)	0.0001	39	0.00001
Moderate vs control	4 (n=1365)	0.85 (0.80–1.34)	>0.10	35	0.00001
Moderate to high vs ASA	7 (n=3457)	0.88 (0.63–1.24)	>0.10	14	0.00001
Moderate + ASA vs ASA	3 (n=480)	0.44 (0.23–0.83)	0.01	16	>0.01
Low + ASA vs ASA	3 (n=8435)	0.91 (0.79–1.06)	>0.01	5	0.05

\*Constellation of death, myocardial infarction, or stroke events per 1000 patients.

Adapted from Anand and Yusuf, 1999.<sup>225</sup>

warfarin alone (mean INR 2.8), and 15% of those on the combination of both drugs (mean INR 2.2; aspirin 75 mg/d). Odds ratios for the combined end point were 0.71 for the combination of warfarin plus aspirin versus aspirin alone (95% CI 0.58 to 0.86;  $P=0.0005$ ), 0.81 for warfarin alone versus aspirin alone (95% CI 0.67 to 0.98;  $P=0.028$ ), and 0.88 for the combination versus warfarin alone (95% CI 0.72 to 1.07;  $P=0.20$ ). The superiority of the combination over aspirin was highly significant at  $P=0.0005$ , but there was no significant difference between the 2 warfarin groups. Major bleeding occurred at a rate of 0.15% per year in the aspirin-alone group, 0.58% per year in the warfarin-alone group, and 0.52% per year in the combination group (222).

Two studies, CARS (210) and the Combined Hemotherapy And Mortality Prevention Study (CHAMP) (223), compared aspirin alone with the combination of aspirin and low-intensity warfarin (lower limit of targeted INR <2.0). The CARS study in 8803 patients with AMI showed that low fixed-dose warfarin (1 or 3 mg/d) plus aspirin (80 mg) was no more effective than aspirin alone (160 mg) for the long-term treatment of survivors of MI (209). Thus, after a mean of 14 months of follow-up, the incidence of death, recurrent MI, or stroke was 8.6 in the aspirin group and 8.4 in the combination of aspirin and warfarin (3 mg/d) group. Despite the lack of increased efficacy, the combined aspirin and warfarin (3 mg/d) group showed an increase in major bleeding. The CHAMP study (223) was an open-label trial that evaluated the relative efficacy and safety of aspirin alone (162 mg/d) and the combination of warfarin (INR 1.5 to 2.5) and aspirin (81 mg/d) in 5059 patients with AMI. There was no difference in total mortality (17.3% versus 17.3%), in nonfatal MI (13.1% versus 13.3%), or in nonfatal stroke (4.7% versus 4.2%). Despite lack of increased efficacy, major bleeding was more common in the combined treatment group.

Indirect support for the efficacy of oral anticoagulants in patients with coronary artery disease also comes from a randomized trial of patients with peripheral arterial disease (224). A relatively high-intensity oral anticoagulant regimen (INR 2.6 to 4.5) produced a significant 51% reduction in mortality (from 6.8% to 3.3% per year) compared with an untreated control group ( $P<0.023$ ).

A meta-analysis of 31 randomized trials of oral anticoagulant therapy published between 1960 and 1999 involving patients with coronary artery disease treated for  $\geq 3$  months, stratified by the intensities of anticoagulation and aspirin

therapy, is shown in Table 6. High-intensity (INR 2.8 to 4.8) and moderate-intensity (INR 2 to 3) oral anticoagulation regimens reduced the rates of MI and stroke but increased the risk of bleeding 6.0- to 7.7-fold. When combined with aspirin, low-intensity anticoagulation (INR <2.0) was not superior to aspirin alone, whereas moderate- to high-intensity oral anticoagulation and aspirin versus aspirin alone seemed promising. There was a modest increase in the bleeding risk associated with the combination (225).

Because a rebound increase in ischemic events has been documented after discontinuation of heparin (226) and LMWH (227,228), the use of oral anticoagulants to prevent reinfarction has been evaluated in several studies. The ischemic event rate was reduced by 65% after 6 months in one study of 102 patients ( $P<0.05$ ) (229). In the Antithrombotic Therapy in Acute Coronary Syndromes (ATACS) trial (230), the combined rate of death, MI, and recurrent ischemia decreased from 27.5% to 10.5% after 2 weeks with an INR of 2.0 to 2.5 in 214 patients ( $P=0.004$ ), but most of the benefit accrued during the earlier phase of heparin therapy. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) (231) pilot study of hirudin versus heparin found a dose-adjusted warfarin regimen (INR 2 to 2.5) superior to a fixed dose (3 mg daily) over 6 months in 506 patients, all of whom were given aspirin concurrently. The 58% difference in the rate of death, MI, or refractory angina was marginally significant, but fewer patients were hospitalized for unstable angina ( $P=0.03$ ).

From the results of these clinical trials, conclusions can be drawn about long-term treatment of patients with acute myocardial ischemia: (1) High-intensity oral anticoagulation (INR  $\approx 3.0$  to 4.0) is more effective than aspirin but is associated with more bleeding; (2) the combination of aspirin and moderate-intensity warfarin (INR 2.0 to 3.0) is more effective than aspirin but is associated with a greater risk of bleeding; (3) the combination of aspirin and moderate-intensity warfarin (INR 2.0 to 3.0) is as effective as high-intensity warfarin and is associated with a similar risk of bleeding; (4) the contemporary trials have not addressed the effectiveness of moderate-intensity warfarin (INR 2.0 to 3.0), and in the absence of direct evidence, it cannot be assumed that moderate-intensity warfarin is any more effective than aspirin in preventing death or reinfarction; and (5) there is no evidence that the combination of aspirin and low-intensity

warfarin (INR <2.0) is more effective than aspirin alone, despite the fact that the combination produces more bleeding.

Therefore, the choice for long-term management involves aspirin alone, aspirin plus moderate-intensity warfarin (INR 2.0 to 3.0), or high-intensity warfarin (INR 3.0 to 4.0). The latter 2 regimens are more effective than aspirin but are associated with more bleeding and are much less convenient to administer. Furthermore, in the absence of tight INR control, the high-intensity regimen has the potential to cause unacceptable bleeding. An alternative approach to long-term antithrombotic management of patients with acute myocardial ischemia is to use a combination of aspirin plus clopidogrel. Recommendations of the choice among these competing approaches is beyond the scope of this review on oral anticoagulants but should be addressed in future recommendations for the management of patients with acute myocardial ischemia.

### Prosthetic Heart Valves

The most convincing evidence that oral anticoagulants are effective in patients with prosthetic heart valves comes from a study of patients randomized to receive warfarin in uncertain intensity versus either of 2 aspirin-containing platelet-inhibitor drug regimens for 6 months (232). The incidence of thromboembolic complications in the group that continued warfarin was significantly lower than that of the groups that received antiplatelet drugs (relative risk reduction 60% to 79%). The incidence of bleeding was highest in the warfarin group. Three studies addressed the minimum effective intensity of anticoagulant therapy. One study of patients with bioprosthetic heart valves found a moderate dose regimen (INR 2.0 to 2.25) as effective as a more intense regimen (INR 2.5 to 4.0) but associated with less bleeding (167). A second study (168), involving patients with mechanical prosthetic heart valves, found no difference in effectiveness between a very high-intensity regimen (INR 7.4 to 10.8) and a lower-intensity regimen (INR 1.9 to 3.6), but the higher-intensity regimen produced more bleeding. Another study (169) of patients with mechanical prosthetic valves treated with aspirin and dipyridamole found no difference in efficacy between moderate-intensity (INR 2.0 to 3.0) and high-intensity (INR 3.0 to 4.5) warfarin regimens, but more bleeding occurred with the high-intensity regimen. A more recent randomized trial showed that addition of aspirin (100 mg/d) to warfarin (INR 3.0 to 4.5) improved efficacy compared with warfarin alone (63). This combination of low-dose aspirin and high-intensity warfarin was associated with a reduction in all-cause mortality, cardiovascular mortality, and stroke at the expense of increased minor bleeding; the difference in major bleeding, including cerebral hemorrhage, did not reach statistical significance. A retrospective study of 16 081 patients with mechanical heart valves in the Netherlands attending 4 regional anticoagulation clinics (target INR 3.6 to 4.8) found a sharp rise in the incidence of embolic events when the INR fell to <2.5, whereas bleeding increased when the INR rose to >5.0 (120).

Guidelines developed by the European Society of Cardiology (233) called for anticoagulant intensity in proportion to the thromboembolic risk associated with specific types of

prosthetic heart valves. For first-generation valves, an INR of 3.0 to 4.5 was recommended. An INR of 3.0 to 3.5 was considered sensible for second-generation valves in the mitral position, whereas an INR of 2.5 to 3.0 was deemed sufficient for second-generation valves in the aortic position. The American College of Chest Physicians guidelines (234) of 2001 recommended an INR of 2.5 to 3.5 for most patients with mechanical prosthetic valves and of 2.0 to 3.0 for those with bioprosthetic valves and low-risk patients with bileaflet mechanical valves (such as the St Jude Medical device) in the aortic position. Similar guidelines have been promulgated conjointly by the American College of Cardiology and the American Heart Association (235). In contrast, a higher upper limit of the therapeutic range (INR 4.8 to 5.0) has been recommended by some European investigators (118,236).


Management of women with prosthetic heart valves during pregnancy and the potential shortcomings of heparin and LMWH in such patients have been discussed in the section on pregnancy.

### Atrial Fibrillation

Five trials with relatively similar study designs have addressed anticoagulant therapy for primary prevention of ischemic stroke in patients with nonvalvular (nonrheumatic) atrial fibrillation. The SPAF study (237), the Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF) (238), and the Stroke Prevention In Nonvalvular Atrial Fibrillation (SPINAF) trial were carried out in the United States (239); the Atrial Fibrillation, Aspirin, Anticoagulation study (AFASAK) was carried out in Denmark (240); and the Canadian Atrial Fibrillation Anticoagulation (CAFA) study (241) was stopped before completion because of convincing results in 3 of the other trials (242). In the AFASAK and SPAF trials, patients also were randomized to aspirin therapy (238,241). The results of all 5 studies were similar; pooled analysis on an intention-to-treat basis showed a 69% risk reduction and >80% risk reduction in patients who remained on treatment with warfarin (efficacy analysis) (243). There was little difference between rates of major or intracranial hemorrhage in the warfarin and control groups, but minor bleeding was ≈3% per year more frequent in the warfarin-assigned groups (244). Pooled results from 2 studies were consistent with a smaller benefit from aspirin. In the AFASAK study, 75 mg daily did not significantly reduce thromboembolism, whereas in the SPAF trial, 325 mg per day was associated with a 44% stroke risk reduction in younger patients.

A secondary prevention trial in Europe (the European Atrial Fibrillation Trial [EAFT]) (245) compared anticoagulant therapy, aspirin, and placebo in patients with atrial fibrillation who had sustained nondisabling stroke or transient ischemic attack within 3 months. Compared with placebo, there was a 68% reduction in stroke with warfarin and an insignificant 16% stroke risk reduction with aspirin. None of the patients in the anticoagulant group suffered intracranial hemorrhage.

The SPAF II (246) trial compared the efficacy and safety of warfarin with aspirin in patients with atrial fibrillation. Warfarin was more effective than aspirin for preventing



**Figure 2.** Advantage of anticoagulation over aspirin for patients with atrial fibrillation in 6 randomized trials: PATAF (249), SPAF II (247), AFASAK II (254), AFASAK I (241), SPAF III (124), and EAFT (246).

ischemic stroke, but this difference was almost entirely offset by a higher rate of intracranial hemorrhage with warfarin, particularly among patients  $>75$  years of age, in whom the rate of intracranial hemorrhage was 1.8% per year. The intensity of anticoagulation was greater in the SPAF trials than in several of the other primary prevention studies; in addition, the majority of intracranial hemorrhages during these trials occurred when the estimated INR was  $>3.0$ . In the SPAF III study (124), warfarin (INR 2.0 to 3.0) was much more effective than a fixed-dose combination of warfarin (1 to 3 mg/d; INR 1.2 to 1.5) plus aspirin (325 mg/d) in high-risk patients with atrial fibrillation, whereas aspirin alone was sufficient for patients at low intrinsic risk of thromboembolism. Whether treatment targeted to the lower end of the therapeutic INR range (near 2) provides much, if not all, the benefit achieved remains to be evaluated in a prospective trial (123). In a Dutch general practice population without established indications for warfarin, neither low- nor standard-intensity anticoagulation was better than aspirin in preventing ischemic events (247).

In summary, the evidence indicates that both warfarin and aspirin are effective for prevention of systemic embolism in patients with nonvalvular atrial fibrillation. Warfarin is more effective than aspirin but is associated with a higher rate of bleeding. As might be expected, randomized trials involving high-risk atrial fibrillation patients (stroke rates  $>6\%$  per year) show larger absolute risk reductions by adjusted-dose warfarin relative to aspirin, whereas the absolute risk reductions are consistently smaller in trials of atrial fibrillation patients with lower stroke rates. Warfarin, adjusted to achieve an INR of 2 to 3, is therefore most advantageous (from the perspective of benefit versus risk) for patients at greatest intrinsic risk. Subgroup analysis of the atrial fibrillation studies identified the following high-risk features: prior stroke or thromboembolism, age  $>65$  years, hypertension, diabetes mellitus, coronary arterial disease, and moderate to severe left ventricular dysfunction by echocardiography (Figure 2) (173).

American College of Cardiology/American Heart Association/European Society of Cardiology guidelines for the management of patients with atrial fibrillation were published in 2001 (248).

### Other Indications for Oral Anticoagulant Therapy

Other widely accepted indications for oral anticoagulant therapy have not been evaluated in properly designed clinical trials. Among these are atrial fibrillation associated with valvular heart disease, and mitral stenosis in the presence of sinus rhythm. Long-term anticoagulation (INR 2.0 to 3.0) also is indicated in patients who have sustained one or more episodes of systemic thromboembolism. Anticoagulants are not presently indicated in patients with ischemic cerebrovascular disease (249,250). Reduced left ventricular systolic function is associated with both stroke and mortality even in the absence of documented atrial fibrillation (251). Warfarin is used frequently in patients with dilated cardiomyopathy, although no randomized trials have confirmed the benefit of anticoagulation (252). Long-term anticoagulant therapy also is indicated in patients with ischemic stroke of unknown origin who have a combination of a patent foramen ovale and atrial septal aneurysm because these patients have an increased the risk of recurrent stroke despite treatment with aspirin (253).

### References

1. Whitton DS, Sadowski JA, Suttie JW. Mechanisms of coumarin action: significance of vitamin K epoxide reductase inhibition. *Biochemistry* 1978;17:1371-7.
2. Fasco MJ, Hildebrandt EF, Suttie JW. Evidence that warfarin anticoagulant action involves two distinct reductase activities. *J Biol Chem* 1982;257:11210-2.
3. Choonara IA, Malia RG, Haynes BP, et al. The relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarin. *Br J Clin Pharmacol* 1988;25:1-7.
4. Trivedi LS, Rhee M, Galivan JH, et al. Normal and warfarin-resistant rat hepatocyte metabolism of vitamin K 2,3 epoxide: evidence for multiple pathways of hydroxyvitamin K formation. *Arch Biochem Biophys* 1988; 264:67-73.
5. Stenflo J, Fernlund P, Egan W, et al. Vitamin K dependent modifications of glutamic acid residues in prothrombin. *Proc Natl Acad Sci U S A* 1974;71:2730-3.
6. Nelsestuen GL, Ztykovicz TH, Howard JB. The mode of action of vitamin K: identification of  $\gamma$ -carboxyglutamic acid as a component of prothrombin. *J Biol Chem* 1974;249:6347-50.
7. Friedman PA, Rosenberg RD, Hauschka PV, et al. A spectrum of partially carboxylated prothrombins in the plasmas of coumarin treated patients. *Biochim Biophys Acta* 1977;494:271-6.
8. Malhotra OP, Nesheim ME, Mann KG. The kinetics of activation of normal and gamma carboxy glutamic acid deficient prothrombins. *J Biol Chem* 1985;260:279-87.
9. Nelsestuen GL. Role of  $\gamma$ -carboxyglutamic acid: an unusual transition required for calcium-dependent binding of prothrombin to phospholipid. *J Biol Chem* 1976;251:5648-56.
10. Prendergast FG, Mann KG. Differentiation of metal ion-induced transitions of prothrombin fragment 1. *J Biol Chem* 1977;252:840-50.
11. Borowski M, Furie BC, Bauminger S, et al. Prothrombin requires two sequential metal-dependent conformational transitions to bind phospholipids: conformation-specific antibodies directed against the phospholipid-binding site on prothrombin. *J Biol Chem* 1986;261: 14969-75.
12. Hauschka PV, Lian JB, Cole DEC, et al. Osteocalcin and matrix Gla protein: vitamin K dependent proteins in bone. *Phys Rev* 1989; 990-1047.
13. Price PA. Role of vitamin K-dependent proteins in bone metabolism. *Annu Rev Nutr* 1988;8:565-83.

14. Maillard C, Berruyer M, Serre CM, et al. Protein S, a vitamin K-dependent protein is a bone matrix component synthesized and secreted by osteoblasts. *Endocrinology* 1992;130:1599-604.
15. Pan LC, Williamson MK, Price PA. Sequence of the precursor to rat bone  $\gamma$ -carboxyglutamic acid protein that accumulated in warfarin-treated osteosarcoma cells. *J Biol Chem* 1985;260:13398-401.
16. Pettifor JM, Benson R. Congenital malformations associated with the administration of oral anticoagulants during pregnancy. *J Pediatr* 1975; 86:459-62.
17. Hall JG, Pauli RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. *Am J Med* 1980;68:122-40.
18. Breckenridge A. Oral anticoagulant drugs: pharmacokinetic aspects. *Semin Hematol* 1978;15:19-26.
19. O'Reilly RA. Vitamin K and other oral anticoagulant drugs. *Annu Rev Med* 1976;27:245-61.
20. Kelly JG, O'Malley K. Clinical pharmacokinetics of oral anticoagulants. *Clin Pharmacokinet* 1979;4:1-15.
21. O'Reilly RA. Warfarin metabolism and drug-drug interactions. In: Wessler S, Becker CG, Nemerson Y, editors. *The New Dimensions of Warfarin Prophylaxis: Advances in Experimental Medicine and Biology*. New York, NY: Plenum; 1986:205-12.
22. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. *Brit J Clin Pharmacol* 1998;45: 525-38.
23. Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. *Lancet* 1999;353:717-9.
24. Higashi M, Veenstra DL, Wittkowsky AK, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. *JAMA* 2002;287:1690-8.
25. Breckenridge A, Orme M, Wesseling H, et al. Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. *Clin Pharmacol Ther* 1974;15:424-30.
26. O'Reilly RA. Studies on the optical enantiomorphs of warfarin in man. *Clin Pharmacol Ther* 1974;16:348-54.
27. O'Reilly RA, Trager WF. Stereoselective interaction of phenylbutazone with 13C/12C labelled racemates of warfarin in man (abstr). *Fed Proc* 1978;37:545.
28. Toon S, Low LK, Gibaldi M, et al. The warfarin-sulfinpyrazone interaction: stereochemical considerations. *Clin Pharmacol Ther* 1986;39: 15-24.
29. O'Reilly RA. The stereoselective interaction of warfarin and metronidazole in man. *N Engl J Med* 1976;295:354-7.
30. O'Reilly RA. Stereoselective interaction of trimethoprim-sulfamethoxazole with the separated enantiomorphs of racemic warfarin in man. *N Engl J Med* 1980;302:33-5.
31. Lewis RJ, Trager WF, Chan KK, et al. Warfarin: stereochemical aspects of its metabolism and the interaction with phenylbutazone. *J Clin Invest* 1974;53:1607-17.
32. O'Reilly RA, Trager WF, Rettie AE, et al. Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans. *Clin Pharmacol Ther* 1987;42:290-4.
33. O'Reilly RA. Lack of effect of fortified wine ingested during fasting and anticoagulant therapy. *Arch Intern Med* 1981;141:458-9.
34. Cropp JS, Bussey HI. A review of enzyme induction of warfarin metabolism with recommendations for patient management. *Pharmacotherapy* 1997;17:917-28.
35. O'Reilly RA, Pool JG, Aggeler PM. Hereditary resistance to coumarin anticoagulant drugs in man and rat. *Ann N Y Acad Sci* 1968;151: 913-31.
36. O'Reilly RA, Aggeler PM, Hoag MS, et al. Hereditary transmission of exceptional resistance to coumarin anticoagulant drugs. *N Engl J Med* 1983;308:1229-30.
37. Alving BM, Strickler MP, Knight RD, et al. Hereditary warfarin resistance: investigation of a rare phenomenon. *Arch Intern Med* 1985;145: 499-501.
38. Oldenburg J, Quenzel EM, Harbrecht U, et al. Missense mutations at ALA-10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy. *Br J Haematol* 1997;98:240-4.
39. Chu K, Wu SM, Stanley T, et al. A mutation in the propeptide of Factor IX leads to warfarin sensitivity by a novel mechanism. *J Clin Invest* 1996;98:1619-25.
40. Mannucci PM. Genetic control of anticoagulation. *Lancet* 1999;353: 688-9.
41. Gurwitz JH, Avorn J, Ross-Degnan D, et al. Aging and the anticoagulant response to warfarin therapy. *Ann Intern Med* 1992;116:901-4.
42. Mungall D, White R. Aging and warfarin therapy. *Ann Intern Med* 1992;117:878-9.
43. Bowles SK. Stereoselective disposition of warfarin in young and elderly subjects (abstr). *Clin Pharmacol Ther* 1994;55:172.
44. O'Reilly R, Rytand D. "Resistance" to warfarin due to unrecognized vitamin K supplementation. *N Engl J Med* 1980;303:160-1.
45. Suttie JW, Mumma-Schendel LL, Shah DV, et al. Vitamin K deficiency from dietary vitamin K restriction in humans. *Am J Clin Nutr* 1988;47:475-80.
46. Sadowski JA, Booth SL, Mann KG, et al. Structure and mechanism of activation of vitamin K antagonists. In: Poller L, Hirsh J, editors. *Oral Anticoagulants*. London, UK: Arnold; 1996:9-29.
47. Bovill EG, Lawson J, Sadowski JA, et al. Mechanisms of vitamin K metabolism and vitamin K-dependent hemostasis: implications for warfarin therapy. In: Ezekowitz MD, editors. *The Heart as a Source of Systemic Embolisation*. New York, NY: Marcel Dekker; 1992.
48. Booth SL, Charnley JM, Sadowski JA, et al. Dietary vitamin K<sub>1</sub> and stability of oral anticoagulation: proposal of a diet with a constant vitamin K<sub>1</sub> content. *Thromb Haemost* 1997;77:504-9.
49. Richards RK. Influence of fever upon the action of 3,3-methylene bis-(4-hydroxycoumarin). *Science* 1943;97:313-6.
50. Owens JC, Neely WB, Owen WR. Effect of sodium dextrothyroxine in patients receiving anticoagulants. *N Engl J Med* 1962;266:76-9.
51. Bechtold H, Andrassy K, Jahnchen E, et al. Evidence for impaired hepatic vitamin K<sub>1</sub> metabolism in patients treated with N-methylthiottetrazole cephalosporins. *Thromb Haemost* 1984;51:358-61.
52. Weitekamp MR, Aber RC. Prolonged bleeding times and bleeding diathesis associated with moxalactam administration. *JAMA* 1983;249: 69-71.
53. O'Reilly RA, Sahud MA, Robinson AJ. Studies on the interaction of warfarin and clofibrate in man. *Thromb Diath Haemorrh* 1972;27: 309-18.
54. Rothschild BM. Hematologic perturbations associated with salicylate. *Clin Pharmacol Ther* 1979;26:145-52.
55. Hylek EM, Heiman H, Skates SJ, et al. Acetaminophen and other risk factors for excessive warfarin anticoagulation. *JAMA* 1998;279: 657-62.
56. Bell WR. Acetaminophen and warfarin: undesirable synergy. *JAMA* 1998;279:702-3.
57. Dale J, Myhre E, Loew D. Bleeding during acetylsalicylic acid and anticoagulant therapy in patients with reduced platelet reactivity after aortic valve replacement. *Am Heart J* 1980;99:746-52.
58. Schulman S, Henriksson K. Interaction of ibuprofen and warfarin on primary haemostasis. *Br J Rheumatol* 1989;28:46-9.
59. Cazenave J-P, Packham MA, Guccione MA, et al. Effects of penicillin G on platelet aggregation, release and adherence to collagen. *Proc Soc Exp Med* 1973;142:159-66.
60. Brown CH II, Natelson EA, Bradshaw W, et al. The hemostatic defect produced by carbenicillin. *N Engl J Med* 1974;291:265-70.
61. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets, I: acetylation of a particulate fraction protein. *J Clin Invest* 1975;56:624-32.
62. Chesebro JH, Fuster V, Elveback LR, et al. Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole. *Am J Cardiol* 1983;51:1537-41.
63. Turpie AG, Gent M, Laupacis A, et al. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. *N Engl J Med* 1993;329:524-9.
64. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. *Lancet* 1998;351:233-41.
65. Weibert RT, Lorentz SM, Townsend RJ, et al. Effect of erythromycin in patients receiving long-term warfarin therapy. *Clin Pharm* 1989;8: 210-24.
66. Lorentz SM, Weibert RT. Potentiation of warfarin anticoagulation by topical testosterone treatment. *Clin Pharm* 1985;4:332-4.
67. Udall JA. Human sources and absorption of vitamin K in relation to anticoagulation stability. *JAMA* 1965;194:127-9.

68. Wells PS, Holbrook AM, Crowther NR, et al. The interaction of warfarin with drugs and food: a critical review of the literature. *Ann Intern Med* 1994;121:676-83.

69. Koch-Weser J, Sellers EM. Drug interactions with oral anticoagulants. *N Engl J Med* 1971;285:487-98.

70. Sellers E, Weser JK. Drug interactions with coumarin anticoagulants. *N Engl J Med* 1971;285:547-58.

71. Wittkowsky AK. Drug interactions updates: drugs, herbs and oral anti-coagulation. *J Thromb Thrombolysis* 2001;12:67-71.

72. Wessler S, Gitel SN. Warfarin: from bedside to bench. *N Engl J Med* 1984;311:645-52.

73. Zivelin A, Rao LV, Rapaport SI. Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin-K dependent clotting factors. *J Clin Invest* 1993; 92:2131-40.

74. Patel P, Weitz J, Brooker LA, et al. Decreased thrombin activity of fibrin clots prepared in cord plasma compared to adult plasma. *Pediatr Res* 1996;39:826-30.

75. Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. *J Clin Invest* 1990; 86:385-91.

76. Furie B, Diuguid CF, Jacobs M, et al. Randomized prospective trial comparing the native prothrombin antigen with the prothrombin time for monitoring anticoagulant therapy. *Blood* 1990;75:344-9.

77. Harrison L, Johnston M, Massicotte MP, et al. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. *Ann Intern Med* 1997;126:133-6.

78. Quick AJ. The prothrombin time in haemophilia and in obstructive jaundice. *J Biol Chem* 1935;109:73-4.

79. Zucker S, Cathey MH, Sox PJ, et al. Standardization of laboratory tests for controlling anticoagulant therapy. *Am J Clin Pathol* 1970;53: 348-54.

80. Poller L. Progress in standardisation in anticoagulant control. *Hematol Rev* 1987;1:225-41.

81. Latallo ZS, Thomson JM, Poller L. An evaluation of chromogenic substrates in the control of oral anticoagulant therapy. *Br J Haematol* 1981;47:307-18.

82. Poller L, Taberner DA. Dosage and control of oral anticoagulants: an international survey. *Br J Haematol* 1982;51:479-85.

83. Kirkwood TBL. Calibration of reference thromboplastins and standardisation of the prothrombin time ratio. *Thromb Haemost* 1983;49: 238-44.

84. Bussey HI, Force RW, Bianco TM, et al. Reliance on prothrombin time ratios causes significant errors in anticoagulation therapy. *Arch Intern Med* 1992;152:278-82.

85. Tripodi A, Chantarangkul V, Braga M, et al. Results of a multicenter study assessing the status of a recombinant thromboplastin for the control of oral anticoagulant therapy. *Thromb Haemost* 1994;72:261-7.

86. Hirsh J. Is the dose of warfarin prescribed by American physicians unnecessarily high? *Arch Intern Med* 1987;147:769-71.

87. World Health Organization Expert Committee on Biological Standardization. 33rd Report Technical Report Series No. 687. Geneva: World Health Organization; 1983.

88. Johnston M, Harrison L, Moffat K, et al. Reliability of the international normalized ratio for monitoring the induction phase of warfarin: comparison with the prothrombin time ratio. *J Lab Clin Med* 1996;128: 214-7.

89. Kovacs MJ, Wong A, MacKinnon K, et al. Assessment of the validity of the INR system for patients with liver impairment. *Thromb Haemost* 1994;71:727-30.

90. College of American Pathologists Coagulation Survey Set: CG2-C. Northfield, IL: College of American Pathologists; 1997.

91. Taberner DA, Poller L, Thomson JM, et al. Effect of international sensitivity index (ISI) of thromboplastins on precision of international normalized ratios (INR). *J Clin Pathol* 1989;42:92-6.

92. Poller L, Hirsh J. Laboratory monitoring of anticoagulants. In: Poller L, Hirsh J, editors. *Oral Anticoagulants*. London, UK: Arnold; 1996: 49-64.

93. Brien WF, Crawford L, Wood DE. Discrepant results in INR testing. *Thromb Haemost* 1994;72:986-7.

94. van den Besselaar AM, Evatt BL, Brogan DR, et al. Proficiency testing and standardization of prothrombin time: effect of thromboplastin, instrumentation, and plasma. *Am J Clin Pathol* 1984;82:688-99.

95. Poller L, Triplett DA, Hirsh J, et al. The value of plasma calibrants in correcting coagulometer effects on international normalized ratios: an international multicenter study. *Am J Clin Pathol* 1995;103:358-65.

96. Poller L, Thomson JM, Taberner DA, et al. The correction of coagulometer effects on international normalized ratios: a multicentre evaluation. *Br J Haematol* 1994;86:112-7.

97. Poller L, Triplett DA, Hirsh J, et al. A comparison of lyophilized artificially depleted plasma and lyophilized plasma from warfarin treated in correcting for coagulometer effects on international normalized ratios. *Am J Clin Pathol* 1995;103:366-71.

98. Poggio M, van den Besselaar AM, van der Velde EA, et al. The effect of some instruments for prothrombin time testing on the International Sensitivity Index (ISI) of two rabbit tissue thromboplastin reagents. *Thromb Haemost* 1989;62:868-74.

99. D'Angelo A, Seveso MP, D'Angelo SV, et al. Comparison of two automated coagulometers and the manual tilt tube method for determination of prothrombin time. *Am J Clin Pathol* 1989;92:321-8.

100. Poller L, Thomson JM, Taberner DA. Effect of automation on the prothrombin time test in NEQAS surveys. *J Clin Pathol* 1989;42: 97-100.

101. Ray MJ, Smith IR. The dependence of the International Sensitivity Index on the coagulometer used to perform the prothrombin time. *Thromb Haemost* 1990;63:424-9.

102. van Rijn JL, Schmidt NA, Rutten WP. Correction of instrument and reagent based differences in determination of the International Normalised Ratio (INR) for monitoring anticoagulant therapy. *Clin Chem* 1989;35:840-3.

103. Thomson JM, Taberner DA, Poller L. Automation and prothrombin time: a United Kingdom field study of two widely used coagulometers. *J Clin Pathol* 1990;43:679-84.

104. Fairweather RB, Ansell J, van den Besselaar AM, et al. Laboratory monitoring of oral anticoagulant therapy: College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy. *Arch Pathol Lab Med* 1998;122:768-81.

105. Ng VL, Levin J, Corash L, et al. Failure of the International Normalized Ratio to generate consistent results within a local medical community. *Am J Clin Pathol* 1993;99:689-94.

106. Poller L. Laboratory control of oral anticoagulants. *Br Med J* 1987; 294:1184.

107. Kazama M, Suzuki S, Abe T, et al. Evaluation of international normalized ratios by a controlled field survey with 4 different thromboplastin reagents. *Thromb Haemost* 1990;64:535-41.

108. van den Besselaar AM, Lewis SM, Mannucci PM, et al. Status of present and candidate International Reference Preparations (IRP) of thromboplastin for the prothrombin time: a report of the Subcommittee for Control of Anticoagulation. *Thromb Haemost* 1993;69:85.

109. Duncan EM, Casey CR, Duncan BM, et al. Effect of concentration of trisodium citrate anticoagulant on calculation of the international normalized ratio and the international sensitivity index of thromboplastin. *Thromb Haemost* 1994;72:84-8.

110. Adcock DM, Kress DC, Marlar RA. Effect of 3.2% vs 3.8% sodium citrate on routine coagulation testing. *Am J Clin Pathol* 1997;107: 105-10.

111. Moll S, Ortell TL. Monitoring warfarin therapy in patients with lupus anticoagulants. *Ann Intern Med* 1997;127:177-85.

112. Della Valle P, Crippa L, Safa O, et al. Potential failure of the International Normalized Ratio (INR) system in the monitoring of oral anticoagulation in patients with lupus anticoagulants. *Ann Med Interne (Paris)* 1996;147 Suppl:10-4.

113. Rapaport SI, Le DT. Thrombosis in the antiphospholipid antibody syndrome. *N Engl J Med* 1995;333:665.

114. Le DT, Weibert RT, Sevilla BK, et al. The international normalized ratio (INR) for monitoring warfarin therapy: reliability and relation to other monitoring methods. *Ann Intern Med* 1994;120:552-8.

115. Lind SE, Callas PW, Golden EA, et al. Plasma levels of factors II, VII, and X and their relationship to the International Normalized Ratio during chronic warfarin therapy. *Blood Coagul Fibrinolysis* 1997;8: 48-53.

116. Kornberg A, Francis CW, Pellegrini VD Jr, et al. Comparison of native prothrombin antigen with the prothrombin time for monitoring oral anticoagulant prophylaxis. *Circulation* 1993;88:454-60.

117. James AH, Britt RP, Raskino CL, et al. Factors affecting the maintenance dose of warfarin. *J Clin Pathol* 1992;45:704-6.

118. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. *Ann Intern Med* 1994;120:897-902.

119. ASPECT Research Group. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. *Lancet* 1994;343:499-503.
120. Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anti-coagulant therapy in patients with mechanical heart valve prostheses: the Leiden artificial valve and anticoagulation study. *N Engl J Med* 1995; 333:11-7.
121. Stroke Prevention in Reversible Ischemia Trial (SPiRiT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. *Ann Neurol* 1997;42:857-65.
122. Mohr JP, Thompson JLP, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. *N Engl J Med* 2001;345:1444-51.
123. Hylek EM, Skates SJ, Sheehan MA, et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with non-rheumatic atrial fibrillation. *N Engl J Med* 1996;335:540-6.
124. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. *Lancet* 1996;348:633-8.
125. Lucas FV, Duncan A, Jay R, et al. A novel whole blood capillary technique for measuring prothrombin time. *Am J Clin Pathol* 1987;88: 442-6.
126. Yano Y, Kambayashi J, Murata K, et al. Bedside monitoring of warfarin therapy by a whole blood capillary coagulation monitor. *Thromb Res* 1992;66:583-90.
127. Leaning KE, Ansell JE. Advances in the monitoring of oral anticoagulation: point-of-care testing, patient self-monitoring, and patient self-management. *J Thromb Thrombolysis* 1996;3:377-83.
128. Jennings I, Luddington RJ, Baglin T. Evaluation of the Ciba Corning Biotrack 512 coagulation monitor for the control of oral anticoagulation. *J Clin Pathol* 1991;44:950-3.
129. McCurdy SA, White RH. Accuracy and precision of a portable anticoagulation monitor in a clinical setting. *Arch Intern Med* 1992;152: 589-92.
130. Tripodi A, Arbini AA, Chantarangkul V, et al. Are capillary whole blood coagulation monitors suitable for the control of oral anticoagulant treatment by the international normalized ratio? *Thromb Haemost* 1993; 70:921-4.
131. Oberhardt BJ, Dermott SC, Taylor M, et al. Dry reagent technology for rapid, convenient measurements of blood coagulation and fibrinolysis. *Clin Chem* 1991;37:520-6.
132. Rose VL, Dermott SC, Murray BF, et al. Decentralized testing for prothrombin time and activated partial thromboplastin time using a dry chemistry portable analyzer. *Arch Pathol Lab Med* 1993;117:611-7.
133. Fabbri N, Messmore H, Balbale S, et al. Pilot study to determine use of a TAS analyzer in an anticoagulation clinic setting (abstr). *Blood* 1995;86 Suppl:869a.
134. Tripodi A, Chantarangkul V, Clerici M, et al. Determination of the International Sensitivity Index of a new near-patient testing device to monitor oral anticoagulant therapy—overview of the assessment of conformity to the calibration model. *Thromb Haemost* 1997;78:855-8.
135. Kaatz AA, White RH, Hill J, et al. Accuracy of laboratory and portable monitor international normalized ratio determinations: comparison with a criterion standard. *Arch Intern Med* 1995;155:1861-7.
136. Ansell J, Becker D, Andrew M, et al. Accurate and precise prothrombin time measurement in a multicenter anticoagulation trial employing patient self-testing (abstr). *Blood* 1995;86 Suppl:864a.
137. Andrew M, Marzinotto V, Adams M, et al. Monitoring of oral anticoagulant therapy in pediatric patients using a new microsample PT device. *Blood* 1995;86 Suppl:863a.
138. Ansell JE, Zweig S, Meyer B, et al. Performance of the AvocetPT prothrombin time system (abstr). *Blood* 1998;92 Suppl:112b.
139. Anderson DR, Harrison L, Hirsh J. Evaluation of a portable prothrombin time monitor for home use by patients who require long-term oral anticoagulant therapy. *Arch Intern Med* 1993;153:1441-7.
140. White RH, McCurdy SA, von Marenhoff H, et al. Home prothrombin time monitoring after the initiation of warfarin therapy: a randomized, prospective study. *Ann Intern Med* 1989;111:730-7.
141. Beyth RJ, Landefeld CS. Prevention of major bleeding in older patients treated with warfarin: results of a randomized trial (abstr). *J Gen Intern Med* 1997;12:66.
142. Hasenkam JM, Knudsen L, Kimose HH, et al. Practicability of patient self-testing of oral anticoagulant therapy by the international normalized ratio (INR) using a portable whole blood monitor: a pilot investigation. *Thromb Res* 1997;85:77-82.
143. Erdman S, Vidne B, Levy MJ. A self-control method for long-term anticoagulation therapy. *J Cardiovasc Surg* 1974;15:454-7.
144. Ansell J, Holden A, Knapic N. Patient self-management of oral anticoagulation guided by capillary (fingerstick) whole blood prothrombin times. *Arch Intern Med* 1989;149:2509-11.
145. Ansell J, Patel N, Ostrovsky D, et al. Long-term patient self-management of oral anticoagulation. *Arch Intern Med* 1995;155: 2185-9.
146. Bernardo A. Experience with patient self-management of oral anticoagulation. *J Thromb Thrombolysis* 1996;2:321-5.
147. Horstkotte D, Piper C, Wiemer M, et al. Improvement of prognosis by home prothrombin estimation in patients with life-long anticoagulant therapy (abstr). *Eur Heart J* 1996;17 Suppl:230.
148. Sawicki PT, Working Group for the Study of Patient Self-Management of Oral Anticoagulation. A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial. *JAMA* 1999;281:145-50.
149. Kortke H, Korfer R. International normalized ratio self-management after mechanical heart valve replacement: is an early start advantageous? *Ann Thorac Surg* 2001;72:44-8.
150. Watzke HH, Forberg E, Svolba G, et al. A prospective controlled trial comparing weekly self-testing and self-dosing with the standard management of patients on stable oral anticoagulation. *Thromb Haemost* 2000;83:661-5.
151. Cromheecke ME, Levi M, Colly LP, et al. Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomized cross-over comparison. *Lancet* 2000;356:97-102.
152. Gadisseur AP, Breukink-Engbers WG, van der Meer FJ, et al. Comparison of the quality of oral anticoagulation therapy through patient self-management versus management by specialized anticoagulation clinics in the Netherlands (abstr). *Thromb Haemost* 2001;86 Suppl: OC161.
153. Kaatz S, Elston-Lafata J, Gooldy S. Anticoagulation therapy home and office evaluation (AT HOME) study (abstr). *Thromb Haemost* 2001;86 Suppl:P779.
154. Wilson R, James AH. Computer assisted management of warfarin treatment. *Br Med J* 1984;289:422-4.
155. White RH, Mungall D. Outpatient management of warfarin therapy: comparison of computer-predicted dosage adjustment to skilled professional care. *Ther Drug Monit* 1991;13:46-50.
156. Poller L, Shiach CR, MacCallum PK, et al. Multicentre randomised study of computerised anticoagulant dosage: European Concerted Action on Anticoagulation. *Lancet* 1998;352:1505-9.
157. Poller L, Wright D, Rowlands M. Prospective comparative study of computer programs used for management of warfarin. *J Clin Pathol* 1993;46:299-303.
158. Ageno W, Turpie AGG. A randomized comparison of a computer-based dosing program with a manual system to monitor oral anticoagulant therapy. *Thromb Res* 1998;91:237-40.
159. White RH, McKittrick T, Hutchinson R, et al. Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. *Ann Intern Med* 1995;122:40-2.
160. Crowther MA, Julian J, McCarty D, et al. Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. *Lancet* 2000;356:1551-3.
161. Whiting AM, Bussey HI, Lyons RM. Comparing different routes and doses of phytonadione for reversing excessive anticoagulation. *Arch Intern Med* 1998;158:2136-40.
162. Crowther MA, Douketis JD, Schnurr T, et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy: a randomized, controlled trial. *Ann Intern Med* 2002;137:251-4.
163. Park BK, Scott AK, Wilson AC, et al. Plasma disposition of vitamin K1 in relation to anticoagulant poisoning. *Br J Clin Pharmacol* 1984;18: 655-62.
164. Ansell J, Hirsh J, Dalen J, et al. Managing oral anticoagulant therapy. *Chest* 2001;119 Suppl:22S-38S.
165. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. *Am J Med* 1989;87:144-52.
166. Landefeld CS, Rosenblatt MW. Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions. *Am J Med* 1989;87:153-9.

167. Hull R, Hirsh J, Jay R, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. *N Engl J Med* 1982;307:1676-81.

168. Turpie AGG, Gunstensen J, Hirsh J, et al. Randomized comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. *Lancet* 1988;1:1242-5.

169. Saour JN, Sieck JO, Mamo LAR, et al. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. *N Engl J Med* 1990;322:428-32.

170. Altman R, Rouvier J, Gurfinkel E, et al. Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. *J Thorac Cardiovasc Surg* 1991;101:427-31.

171. Levine MN, Raskob G, Landefeld S, et al. Hemorrhagic complications of anticoagulant treatment. *Chest* 1995;108 Suppl:276s-90s.

172. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. *Am J Med* 1998;105:91-9.

173. Hart RG, Halperin JL. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. *Ann Intern Med* 1999;131:688-95.

174. Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. *N Engl J Med* 1997;336:1506-11.

175. Sindet-Pedersen S, Ramstrom G, Bernvil S, et al. Hemostatic effect of tranexamic acid mouthwash in anticoagulant-treated patients undergoing oral surgery. *N Engl J Med* 1989;320:840-3.

176. Souto JC, Oliver A, ZuaZu-Jausoro I, et al. Oral surgery in anticoagulated patients without reducing the dose of oral anticoagulant: a prospective randomized study. *J Oral Maxillofac Surg* 1996;54:27-32.

177. Sbarouni E, Oakley CM. Outcome of pregnancy in women with valve prostheses. *Br Heart J* 1994;71:196-201.

178. Hanania G. Management of anticoagulants during pregnancy. *Heart* 2001;86:125-6.

179. Montalescot G, Polle V, Collet JP, et al. Low molecular weight heparin after mechanical heart valve replacement. *Circulation* 2000;101:1083-6.

180. McKenna R, Cole ER, Vasan U. Is warfarin sodium contraindicated in the lactating mother? *J Pediatr* 1983;103:325-7.

181. Lao TT, de Swiet M, Letsky E, et al. Prophylaxis of thromboembolism in pregnancy: an alternative. *Br J Obstet Gynecol* 1985;92:202-6.

182. Verhagen H. Local hemorrhage and necrosis of the skin and underlying tissues at starting therapy with dicumarol or dicumacyl. *Acta Med Scand* 1954;148:455-67.

183. Weinberg AC, Lieskovsky G, McGehee WG, et al. Warfarin necrosis of the skin and subcutaneous tissue of the male genitalia. *J Urol* 1983;130:352-4.

184. Broekmans AW, Bertina RM, Loeliger EA, et al. Protein C and the development of skin necrosis during anticoagulant therapy. *Thromb Haemost* 1983;49:244-51.

185. Zauber NP, Stark MW. Successful warfarin anticoagulation despite protein C deficiency and a history of warfarin necrosis. *Ann Intern Med* 1986;104:659-60.

186. Samama M, Horellou MH, Soria J, et al. Successful progressive anticoagulation in a severe protein C deficiency and previous skin necrosis at the initiation of oral anticoagulation treatment. *Thromb Haemost* 1984;51:332-3.

187. Grimaudo V, Gueissaz F, Hauert J, et al. Necrosis of skin induced by coumarin in a patient deficient in protein S. *BMJ* 1989;298:233-4.

187a. Mohr JP, Thompson JLP, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. *N Engl J Med* 2001;345:1444-51.

188. Sevitt S, Gallagher NG. Prevention of venous thrombosis and pulmonary embolism in injured patients. *Lancet* 1959;II:981-9.

189. Francis CW, Marder VJ, Evarts CM, et al. Two-step warfarin therapy: prevention of postoperative venous thrombosis without excessive bleeding. *JAMA* 1983;249:374-8.

190. Powers PJ, Gent M, Jay RM, et al. A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip. *Arch Intern Med* 1989;149:771-4.

191. Taberner DA, Poller L, Burslem RW, et al. Oral anticoagulants controlled by the British comparative thromboplastin versus low-dose heparin in prophylaxis of deep vein thrombosis. *BMJ* 1978;1:272-4.

192. Poller L, McKernan A, Thomson JM, et al. Fixed minidose warfarin: a new approach to prophylaxis against venous thrombosis after major surgery. *Br Med J* 1987;295:1309-12.

193. Bern MM, Lokich JJ, Wallach SR, et al. Very low doses of warfarin can prevent thrombosis in central venous catheters: a randomized prospective trial. *Ann Intern Med* 1990;112:423-8.

194. Poller L, MacCallum PK, Thomson JM, et al. Reduction of factor VII coagulant activity (VIIc), a risk factor for ischaemic heart disease, by fixed dose warfarin: a double blind crossover study. *Br Heart J* 1990;63:231-3.

195. Dale C, Gallus A, Wycherley A, et al. Prevention of venous thrombosis with minidose warfarin after joint replacement. *BMJ* 1991;303:224.

196. Fordyce MJF, Baker AS, Staddon GE. Efficacy of fixed minidose warfarin prophylaxis in total hip replacement. *BMJ* 1991;303:219-20.

197. Poller L, Thomson JM, MacCallum PK, et al. Minidose warfarin and failure to prevent deep vein thrombosis after joint replacement surgery despite inhibiting the postoperative rise in plasminogen activator inhibitor activity. *Clin Appl Thromb Hemost* 1995;1:267-73.

198. Levine M, Hirsh J, Gent M, et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. *Lancet* 1994;343:886-9.

199. Hirsh J. The optimal duration of anticoagulant therapy for venous thrombosis. *N Engl J Med* 1995;332:1710-11.

200. Hirsh J, Lee A. How we diagnose and treat deep vein thrombosis. *Blood* 2002;99:3102-10.

201. Hull R, Delmore T, Gent M, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. *N Engl J Med* 1979;301:855-8.

202. Hull R, Delmore T, Carter C, et al. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. *N Engl J Med* 1982;306:189-94.

203. Lagerstedt CI, Fagher BO, Albrechtsson U, et al. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. *Lancet* 1985;2:515-8.

204. Schulman S, Rhedin A, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. *N Engl J Med* 1995;332:1661-5.

205. Schulman S, Granqvist S, Holmstrom M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism: Duration of Anticoagulation Trial Study Group. *N Engl J Med* 1997;336:393-8.

206. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy: Duration of Anticoagulation Study Group. *Am J Med* 1998;104:332-8.

207. Simioni P, Prandoni P, Zanon E, et al. Deep venous thrombosis and lupus anticoagulant: a case-control study. *Thromb Haemost* 1996;76:187-9.

208. Rance A, Emmerich J, Fiessinger JN. Anticardiolipin antibodies and recurrent thromboembolism. *Thromb Haemost* 1997;77:221-2.

209. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. *N Engl J Med* 1999;340:901-7.

210. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. *Lancet* 1997;350:389-96.

211. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. *N Engl J Med* 1997;336:153-62.

212. Veterans Administration Cooperative Study. Anticoagulants in acute myocardial infarction: results of a cooperative clinical trial. *JAMA* 1973;225:724-9.

213. Drapkin A, Merskey C. Anticoagulant therapy after acute myocardial infarction: relation of therapeutic benefit to patient's age, sex, and severity of infarction. *JAMA* 1972;222:541-8.

214. Medical Research Council Group. Assessment of short-term anticoagulant administration after cardiac infarction: report of the Working Party on Anticoagulant Therapy in Coronary Thrombosis. *BMJ* 1969;1:335-42.

215. Cairns JA, Hirsh J, Lewis HD Jr, et al. Antithrombotic agents in coronary artery disease. *Chest* 1992;102 Suppl:456s-81s.

216. Goldberg RJ, Gore JM, Dalen JE, et al. Long-term anticoagulant therapy after acute myocardial infarction. *Am Heart J* 1985;109:616-22.

217. Leizorovicz A, Boissel JP. Oral anticoagulant in patients surviving myocardial infarction: a new approach to old data. *Eur J Clin Pharmacol* 1983;24:333-6.

218. Sixty-Plus Reinfarction Study Group. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. *Lancet* 1980;2:989-94.

219. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. *N Engl J Med* 1990;323:147-52.

220. van Es RF. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis-2. Abstract presented at the 22nd meeting of the European Society of Cardiology, Amsterdam, 2000. Available at: <http://www.cardiosource.com/trials/trial?searchtoc=A&published=n&uid=MDTRIALS.42057>.

221. Brower MA. Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis-2. Abstract presented at the 22nd meeting of the European Society of Cardiology, Amsterdam, 2000. Available at: <http://www.cardiosource.com/trials/trial?searchtoc=A&published=n&uid=MDTRIALS.32678>.

222. Hurlen M, Smith P, Abdelnoor M, et al. Warfarin Aspirin Reinfarction Study II: Effects of warfarin, aspirin and the two combined, on mortality and thromboembolic morbidity after myocardial infarction. Abstract presented at the 23rd meeting of the European Society of Cardiology, Stockholm, 2001. Available at: <http://www.escardio.org/congress/Stock01/hotline/slides/WARIS%20II%20Press.pdf>.

223. Fiore LD, Ezekowitz MD, Brophy Mt, et al. Department of Veterans Affairs Cooperative Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. *Circulation* 2002;105:557-63.

224. Kretschmer G, Wenzl E, Schemper M, et al. Influence of postoperative anticoagulant treatment on patient survival after femoropopliteal vein bypass surgery. *Lancet* 1988;1:797-8.

225. Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. *JAMA* 1999;282:2058-67.

226. Theroux P, Waters D, Lam J, et al. Reactivation of unstable angina following discontinuation of heparin. *N Engl J Med* 1992;327:141-5.

227. The FRISC Study Group. Low-molecular-weight heparin during instability in coronary artery disease. *Lancet* 1996;347:561-8.

228. Cohen M, Théroux P, Weber S, et al. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. *Int J Cardiol* 1999;71:273-81.

229. Williams DO, Kirby MG, McPherson K, et al. Anticoagulant treatment in unstable angina. *Br J Clin Pract* 1986;40:114-6.

230. Cohen M, Adams PC, Parry G, et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users: primary end point analysis from the ATACS trial. *Circulation* 1994;89:81-8.

231. Anand SS, Yusuf S, Pogue J, et al. Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: Organization to Assess Strategies for Ischemic Syndromes (OASIS) pilot study results. *Circulation* 1998;98:1064-70.

232. Mok CK, Boey J, Wang R, et al. Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective clinical trial. *Circulation* 1985;72:1059-63.

233. Gohlke-Barwolf, Acar J, Oakley C, et al. Guidelines for prevention of thromboembolic events in valvular heart disease: Study Group of the Working Group on Valvular Heart Disease of the European Society of Cardiology. *Eur Heart J* 1995;16:1320-30.

234. Stein PD, Alpert JS, Dalen JE, et al. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. *Chest* 1998;114 Suppl:602S-10S.

235. ACC/AHA guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). *J Am Coll Cardiol* 1998;32:1486-588.

236. Vongpatanasin W, Hillis LD, Lange RA. Prosthetic heart valves. *N Engl J Med* 1996;335:407-16.

237. The Stroke Prevention in Atrial Fibrillation Investigators. The stroke prevention in atrial fibrillation study: final results. *Circulation* 1991;84:527-39.

238. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. *N Engl J Med* 1990;323:1505-11.

239. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation: Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. *N Engl J Med* 1992;327:1406-12.

240. Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK Study. *Lancet* 1989;1:175-9.

241. Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. *J Am Coll Cardiol* 1991;18:349-55.

242. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. *Arch Intern Med* 1994;154:1449-57.

243. Albers GW, Sherman DG, Gress DR, et al. Stroke prevention in nonvalvular atrial fibrillation: a review of prospective randomized trials. *Ann Neurol* 1991;30:511-8.

244. Atwood J, Albers G. Anticoagulation and atrial fibrillation. *Herz* 1993;18:27-38.

245. European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. *Lancet* 1993;342:1255-62.

246. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. *Lancet* 1994;343:687-91.

247. Hellermann BS, Langenberg M, Lodder J, et al. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. *BMJ* 1999;319:958-64.

248. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC Guidelines for the management of patients with atrial fibrillation: executive summary. *J Am Coll Cardiol* 2001;38:1231-66.

249. Sherman DG, Dyken ML, Gent M, et al. Antithrombotic therapy for cerebrovascular disorders: an update. *Chest* 1995;108:444S-56S.

250. Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. *N Engl J Med* 2001;345:1444-51.

251. Fuster V, Gersh BJ, Giuliani ER, et al. The natural history of idiopathic dilated cardiomyopathy. *Am J Cardiol* 1981;47:525-31.

252. Pullicino PM, Halperin JL, Thompson JL. Stroke in patients with heart failure and reduced left ventricular ejection fraction. *Neurology* 2000;54:288-94.

253. Mas JL, Arquizan C, Lamy C, Zuber M, et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. *N Engl J Med* 2001;345:1740-6.

254. Gullov AL, Koefoed BG, Petersen P, et al. Fixed mididose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study (AFASAK 2). *Arch Intern Med* 1998;158:1513-21.

KEY WORDS: AHA/ACC Scientific Statements ■ anticoagulants ■ coagulation ■ hemorrhage ■ thrombus